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INTRODUCTION: Chronic kidney disease is a serious public health concern because of the 
large physical and economic burden on society.  Because of this large burden, it is important to 
determine what factors are associated with the development and progression of the disease, 
especially in early stages.  Physical activity has been shown to be related to many risk factors for 
CKD; however, few studies have assessed its direct relationship with kidney function.  
METHODS: Using data from NHANES, a nationally representative U.S., we described physical 
activity by various intensities, gender and race/ethnicity (paper 1).  W e then investigated the 
cross-sectional relationship between varying intensities of objectively assessed physical activity 
and kidney function in the same population (paper 2).  Using data from the Strong Heart Study, 
an American Indian cohort at high risk for CKD, we investigated the relationship between 
subjectively assessed physical activity with kidney function prospectively (paper 3). RESULTS: 
We showed that Mexican Americans were more physically active than whites and blacks at all 
levels of intensity, in contrast to findings using questionnaires.  W e also confirmed that light 
intensity activity made the largest contribution to total movement.  In paper 2, we showed that 
objectively assessed light intensity physical activity was independently associated with kidney 
function while objectively and subjectively assessed moderate to vigorous physical activity was 
not.  In paper 3 we showed that physical inactivity was associated with rapid declines and kidney 
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function over a five year period.  Physical inactivity was also associated with development of 
kidney damage over a ten year period. PUBLIC HEALTH SIGNIFICANCE: The results of 
these three papers show that physical activity of various intensities are related to kidney function 
and that physical activity may also preserve kidney function over time in a high risk population.  
Previous recommendations for physical activity and health were unable to discuss the benefits of 
physical activity on kidney function because the paucity of evidence.  This study is of public 
health significance because it adds to the growing body of evidence for which we can base our 
future recommendations.       
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1.0  INTRODUCTION 
Chronic kidney disease (CKD) is the progressive deterioration of renal function eventually 
leading to renal failure, also called End Stage Renal Disease (ESRD).  CKD is of immense 
public health concern and expected to become a bigger problem in the coming decades.  There 
are a number of reasons that CKD is an important public health concern: 1) the high prevalence 
of the disease 2) the disproportionate burden on certain age and ethnic groups 3) the high risk for 
adverse health outcomes 4) and the high economic cost.  Despite these factors, CKD awareness 
and prevention efforts remain low in the US [1].   
It is important to consider the number of people affected by this condition.  Worldwide 
prevalence of CKD ranges from 4-16% in adults greater than18 years of age [2-8].  A study of 
the US population using the National Health and Nutrition Examination Survey (NHANES) 
estimates that from 1999-2004, approximately 17% of adults greater than 20 years of age had 
CKD [9].  This was an increase of approximately 16% compared to NHANES data from 1988-
1994.  While the vast majority of individuals with CKD are in early stages of renal disease, the 
final stage of CKD is also growing in prevalence.  In 2000, there were approximately 400,000 
people with ESRD in the United States which is double the number of cases reported in 
1991[10].  B y 2030, t he estimated prevalence of ESRD is projected to reach over 2 m illion 
people [11-13].   
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While the prevalence of CKD can be seen across all racial/ethnic and age groups the 
burden of the disease is not distributed equally across these groups.  The prevalence of CKD is 
greater in older adults with approximately 40% of individuals greater than 65 years of age having 
CKD in the United States and internationally [2].  Similarly, ethnic minorities also experience a 
higher burden of CKD compared to non-Hispanic whites [9]. It has been reported that ethnic 
minorities represents half of the total ESRD population [10, 14].     
Although improvements in survival have been seen in recent years, individuals with CKD 
are still at high risk for early mortality.  Only 35% of the individuals on dialysis, a treatment for 
ESRD, can expect to live 5 years [15]. Currently, the Centers for Disease Control and Prevention 
(CDC) lists kidney disease as the ninth leading cause of death in the United States [16].  The 
mortality rates for CKD are likely higher considering it increases the risk of death from other 
causes.  Individuals with ESRD experience a 10 t o 30 f old increase risk of death from 
cardiovascular events such as coronary heart failure, myocardial infarction, and stroke compared 
to the general population [17].   Non-fatal cardiovascular events are also common in this 
population [18].  The National Kidney Foundation Task Force has recommended that individuals 
with CKD be regarded as having the highest risk for CVD [19, 20].  According to the United 
States Renal Data Systems (USRDS), patients with CKD have a 2 to 4 fold higher rates of stroke 
compared to the non-CKD population [21].   
In addition to the physical toll that CKD places on i ndividuals there is also a large 
economic cost associated with the disease.  A ccording to the USRDS, spending in 2006 on  
patients with ESRD reached $23 billion which represented 6.4% of total Medicare spending 
despite the fact patients with ESRD represents only 1% of the Medicare population [21].  The 
cost of care for individuals with ESRD may reach 6 t imes the cost of an individual without 
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ESRD [22].  A population based study in Germany also indicated that the 10-year cost of CKD 
and its associated morbidities was 65% higher for individuals with CKD compared to individuals 
without CKD [23].  With the projected prevalence of ESRD expected to reach 2 million in the 
next two decades, the growing cost could represent a major problem to our economic and health 
care systems [13].  More effort needs to be directed at identifying individuals at early stages of 
the disease and identifying factors which can slow its progression.     
It’s worth restating that CKD is an enormous public health problem but the development 
of CKD is not inevitable and its rate of progression is highly variable.   S tudies have reported 
annual declines in GFR ranging from 2- 20 mL/min in patients with diabetic nephropathy [24-
26].  The variability in the rate of CKD progression is what makes it important to identify all 
potentially modifiable factors for which intervention efforts can then be focused.  There have 
been numerous intervention efforts which have focused on treating hypertension 
pharmacologically which have proven to be effective at reducing CKD outcomes [27-29].  In 
addition, obesity is another modifiable risk factor which has shown to be independently related 
to CKD [30-32].  I ntervention efforts aimed at weight loss have proven to be effective at 
reducing albuminuria, systolic blood pressure, and preventing further decline in renal function 
[33].  Most of these studies however, focused on diet or surgical treatments to obesity with few 
including physical activity as part of a l ifestyle approach [33].  The role of physical activity in 
reducing the risk of CKD has not yet been determined.  F urther investigation is needed to 
examine the effects of activity on the progression of the CKD.   
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1.1 PHYSICAL ACTIVITY AND CHRONIC KIDNEY DISEASE 
Physical activity has been shown to have a positive effect on many chronic conditions such as 
cardiovascular disease and diabetes [34].  A survey of nephrologists at the World Congress on 
Nephrology also indicated a w idespread belief that a sedentary lifestyle is an important risk 
factor in individuals with CKD [35].  Increasing levels of physical activity and reducing levels of 
inactivity continue to be two of our nation’s health goals, as documented by Healthy People 2010 
[36].  Despite this, physical activity levels are low in the general population and especially 
among individuals with CKD [37].   
Population based studies of the US population have shown that individuals with CKD are 
less active than the general population [38].  A study by Stengel et al examined cross-sectional 
data from NHANES II and showed that physically inactive individuals had over twice the 
prevalence of CKD compared to very active individuals [39].  Studies internationally have found 
similar results, identifying low levels of physical activity among individuals with decreased renal 
function [40].  In patients with ESRD, physical activity levels may also be low due to the fact 
that their capacity for exercise may be reduced.  In the Wave 2 of  the Dialysis Morbidity and 
Mortality Study, less than half of the study participants on dialysis engaged in physical activities 
more than once per week and 75% reported limitations in their ability to engage in vigorous 
physical activity [41].  These reported limitations in their exercise capacity were associated with 
an increase risk for mortality in this population [42, 43].  Studies have also indicated that having 
a reduced capacity for exercise contributes to diminished health related quality of life [23, 44].  
Even though exercise capacity is diminished in individuals with ESRD, it’s important to note 
that exercise training has been shown to improve aerobic capacity, physical function, and health 
related quality of life in these individuals [45-49]. 
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There is also some evidence to suggest that physical activity can be effective at 
preventing the development of CKD.  The benefits of physical activity in preserving renal health 
may be related to its effect on important risk factors for CKD.  Physical activity, along with 
dietary changes and weight loss, has been shown to prevent and or delay the onset of many 
chronic conditions such as diabetes, the leading cause of CKD [50].  In addition to preventing the 
development of diabetes in high risk individuals, physical activity may help individuals to better 
manage their diabetes through glucose control which is important for preventing diabetic 
complications such as CKD [51].  Blood pressure control is also key, especially among 
individuals with diabetes, in preventing CKD development and progression [52].  Physical 
activity has also been shown to reduce blood pressure, especially in individuals with 
hypertension [53].  Other potentially important factors in preventing CKD progression such as, 
improving lipid profiles and reducing levels of inflammation, may be achieved through 
increasing physical activity [54, 55].     
While there is a lot of evidence supporting the relationship between physical activity and 
risk factors for CKD, few studies in humans have looked at the association between physical 
activity and markers of renal function.  Animal models have provided biological plausibility for 
the relationship between physical activity and CKD.  Several studies have shown that moderate 
physical activity reduces renal injury and slows the progression of CKD in rats [56-58].  Few 
studies have explored the relationship between physical activity and renal function in humans.   
The AusDiab study found that physical activity was associated with albuminuria (a marker for 
renal damage) at baseline but failed to find a longitudinal association between physical activity 
and estimated glomerular filtration rate (eGFR) over the five years of study follow-up [59].  In 
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contrast, results from the Cardiovascular Health Study (CHS) indicated that physical inactivity 
was associated with faster declines in renal function during follow-up [60].  
One of the major limitations of the AusDiab and the CHS was the lack of racial diversity.  
Ethnic minorities experience a higher burden of CKD, and studies which examined the 
association between moderate activity and renal function in high risk minority populations are 
scarce [61].  In the current effort, we hope to add to the literature by examining the association 
between physical activity and CKD in two racially diverse populations (NHANES and SHS).    
In addition to having a better understanding about the relationship between CKD and 
physical activity in minority populations, there needs to be a better understanding about the 
specific intensity levels required to affect renal function.  In other words, must the activity be 
performed at a moderate to vigorous level or is light physical activity also important?  Results 
from the AusDiab study using accelerometery have shown that light intensity physical activity is 
related to 2-hour fasting plasma glucose and overall metabolic risk (cluster of variables related to 
metabolic syndrome: HDL cholesterol, triglycerides, systolic and diastolic blood pressure, waist 
circumference, and fasting plasma glucose) independent of activities of moderate intensity [62, 
63].  Due to the fact that metabolic risk factors are associated with CKD, it is possible that light 
physical activity may also be related to CKD [64].  U sing data from NHANES which has 
incorporated accelerometers as part of their physical activity assessment, we will address 
questions about the level of intensity needed to effect renal function. 
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1.2 STUDY GOALS 
The aim of this dissertation is to examine the relationship between subjectively and objectively 
assessed physical activity with CKD/renal function in both a nationally representative and a high 
risk minority population.  S pecifically we plan to use accelerometers to objectively assess 
physical activity, which have the ability to measure a range of intensities of physical activity.  In 
manuscript 1 we plan to describe objectively measured physical activity by race/ethnicity and 
gender in a nationally representative sample (NHANES).  We will then examine the association 
between the various intensities of physical activity and renal function in the same nationally 
representative sample (manuscript 2).  In addition to examining the cross sectional relationship 
between physical activity and renal function in a nationally representative sample, we will also 
examine the longitudinal effects of physical activity on r enal function in a high risk minority 
population.  Using data from the Strong Heart Study (SHS), a study of 13 American Indian tribes 
from 3 geographical locations, we will assess the association between baseline levels of physical 
activity and the 10 year incident CKD (manuscript 3).  Specific aims for each manuscript will be 
described in more detail below.   
 
1. Describe various intensity levels of physical activity objectively by race/ethnicity and 
gender in a nationally representative sample (Manuscript 1). 
Previous examinations using physical activity questionnaires have revealed low levels 
of physical activity especially among ethnic minorities such as black and Mexican 
Americans.  T otal physical activity which is most largely composed of activities of lower 
intensity, and unstructured activity may be relatively more important metabolically.  T o 
address questions related to total physical activity, an objective measure of physical activity 
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is needed as the ability to assess light physical activity by questionnaire is limited.  Using 
data from the 2003-2004 NHANES study cycle, we will describe all intensities of physical 
activity (light, moderate to vigorous, total) and sedentary activities by race/ethnicity and 
gender.  This will provide the background for additional investigations examining intensity 
of activity in NHANES and renal function. 
       
2. Examine the association between objectively assessed physical activity and renal function 
in a nationally representative sample (manuscript 2). 
To date, all of the studies examining the association between physical activity and 
renal function have used subjective questionnaires.  As mentioned above, questionnaires 
have the ability to accurately assess activities of moderate to vigorous intensity but are 
limited in their ability to assess activities of lower intensity.  T he accelerometer has the 
ability to also capture light intensity physical activity which allows it to  measure “total” 
physical activity (the combination of light and moderate to vigorous activity) better than the 
questionnaire.  This analysis will examine the association between activities of light 
intensity, moderate to vigorous physical activity, and total physical activity, which is 
combination of both light and moderate to vigorous activity, with renal function in a 
nationally representative population.  It is hypothesized that higher amounts of total physical 
activity (light and moderate to vigorous physical activity) are associated with higher renal 




3. To determine the association between subjectively assessed physical activity with the 
development of CKD in American Indians.  Using data from the SHS, we will assess the 
association between baseline levels of subjectively assessed physical activity and the 10 
year incidences of CKD.  W e will also examine the association between baseline 
(subjectively assessed) physical activity with change in renal function over the same time 
frame (manuscript 3). 
Few studies have examined the association between physical activity and CKD or 
renal function prospectively.  E ven fewer have examined this association in minority 
populations such as Native Americans where risk of CKD development is high.  The SHS is 
a longitudinal study of 13 American Indian tribes from three locations (Phoenix, Oklahoma, 
North and South Dakota) which was designed to examine cardiovascular morbidity, mortality 
and CVD risk factors.  The SHS assessed physical activity subjectively with the Modifiable 
Activity Questionnaire and collected measures of renal function during examination visits 
(Examination I: 1989-1991; Examination II: 1993-1995; Examination III: 1998-1999, 
respectively).  It is hypothesized that higher levels of baseline physical activity will be 
associated with lower odds of developing renal disease.  Higher levels of baseline physical 
activity will also be associated with a slower decline in renal function.   
1.3 PUBLIC HEALTH SIGNIFICANCE 
Chronic kidney disease is of serious public health concern because of the large burden on society 
both physically and economically [65].  Because of the large burden of the disease, it is 
important to determine what factors are associated with CKD and renal function at early stages 
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of the disease.  The benefits of physical activity to renal health have been demonstrated in a few 
studies but there are still questions which remain unanswered.  One of the unanswered questions 
is related to the longitudinal effects of physical activity on renal function.  The few studies which 
have sought to address this question in humans have revealed conflicting results [59, 60].  As the 
benefits of physical activity for preserving renal function are unproven, further examination is 
warranted.  There are also few studies which have examined the association between physical 
activity and CKD in high risk minority groups.  This current effort will examine this relationship 
in a minority group noted as being at high risk for developing CKD.   
In addition to having a better understanding about the relationship between CKD and 
physical activity in minority populations, there needs to be a better understanding about the 
intensity level required to effect renal function.  As a result of the incorporation of 
accelerometers to assess physical activity in NHANES, we are now able to measure activities of 
lower intensity and unstructured activities.  This addition to the activity assessment in NHANES 
will allow us to examine the total volume of physical activity. It is likely that total physical 
activity, which is a combination of light and moderate to vigorous activity, is more related to 
renal function than moderate to vigorous physical activity alone.   This current effort will 
describe all intensities of physical activity objectively in a nationally representative population 
and examine their association with renal function.  T his will provide us with more insight on 
how physical activity relates to CKD. 
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2.0  CHAPTER 2 
2.1 OVERVIEW OF RENAL FUNCTION 
The human body carries out an important process of breaking down material to be utilized for 
energy, maintaining cell structure, as well as other important functions.  In this process of 
metabolism, waste products are generated that need to be removed from the body.  The kidneys 
are two bean shaped organs located in the middle of the back just below the rib cage whose 
major function is to remove these wastes from the body.  T he kidney has other important 
functions which help to maintain chemical balance in the body through the secretion and 
degradation of enzymes and hormones, as well as regulating the body’s fluid volume and 
electrolyte balance.  The kidneys are involved with the secretion of erythropoietin and calcitriol 
(1,25 OH vitamin D), which has important functions in red blood cell formation and bone health 
[66].  T he kidneys also have an important function for regulating blood pressure by secreting 
renin which activates the renin-angiotensin system (RAS).  The body’s fluid volume is regulated 
by controlling the amount of water and sodium that are excreted in the urine.  The regulation of 
fluid volume and electrolyte balance (e.g. potassium and magnesium levels) have important 
implications for a number of the body’s functions including, blood pressure, cardiac output, and 
cell membrane potentials and excitability.   
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The kidneys are highly vascular organs receiving 20% of resting blood volume.  A s 
plasma flows through and is filtered by the kidney, the rate of plasma clearance over a unit of 
time (glomerular filtration rate or GFR) can be used to assess kidney function [67].  In normal 
kidneys, the GFR is between 90-130 mL/min/1.73m2.  After the age of 40, GFR decreases by 
approximately 8 mL/min/1.73m2 a decade [68].  There are also other factors such as diabetes and 
hypertension which can hasten this decline in GFR that will be discussed in more detail later.   
The functional units of the kidneys where filtration actually occurs are called nephrons.  
Each kidney has about one million nephrons, more than what the body needs to sustain normal 
filtration.  The overall GFR is the sum of all of the single nephron GFR’s.  The nephrons consist 
of a glomerulus where filtration occurs and tubules, which play a role in secretion and 
reabsorption of molecules.  The size/structure and ionic charge of the glomerular basement 
membrane help to control the filtration of water and smaller molecules and provides a barrier 
against filtration of larger molecules.  If a l arger molecule such as albumin is able to pass 
through this barrier, it may indicate a loss in the charge and/or size selectivity barrier.  Not only 
can changes in filtration result from changes in membrane permeability it can also be the result 
of changes in pressure in the glomerulus.  The pressure is controlled by constriction or dilation of 
the afferent and efferent arterioles.  As nephrons become non-functional by disease, the response 
is to increase the pressure in the remaining nephrons.  While this helps preserve overall GFR, in 
the long-term the increase in pressure leads to damage of the remaining nephrons.  This 
contributes to progression of kidney disease [69].   
As stated earlier, glomerular filtration is one of the key functions of the kidney and 
assessing the rate of that filtration has important clinical implications.  Glomerular filtration rate 
can either be measured directly or indirectly by measuring the level of markers present in either 
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the urine or blood.  Key to measuring GFR is the choosing of a marker that is not reabsorbed or 
secreted by the kidney, can pass through the glomerular membranes freely, and is not 
metabolized by the kidney.  Inulin has all of these properties and is regarded as the ideal marker 
to directly measure GFR [70, 71].  Direct measures of inulin clearance involve continuous 
intravenous infusion of inulin which is then collected in the urine through bladder 
catheterization.  T his method is not practical in clinical or research settings which prompted 
other measures to be developed.  Other widely used markers include 125I-iothalamate, 99mTc-
diethylenetriaminepenta-acetic acid, and 51Cr-ehylenediaminetetra-acid, which can be detected in 
the urine or blood to get a measure of GFR.   
There are also indirect ways to estimate GFR that may be less accurate but more feasible 
in research and/or clinical settings.  Measures of serum creatinine levels can be used to estimate 
GFR through the use of simple formulas.  The formulas are necessary to account for differences 
in creatinine generation, due to differences in muscle mass.  The Modification of Diet in Renal 
Disease study developed such an equation to estimate GFR: 
 
eGFR = 186.3 X serum creatinine (mg/dL) -1.154 X age -0.203 (X 0.742 for women) (X 1.21 
for Non-Hispanic Black) [72] 
Another equation by Cockcroft-Gault estimates creatinine clearance with the following 
formula: 
Cc = [(140-age) X weight (kg) (X 0.85 if female) / (72/ serum creatinine)][73]     
 
These equations are widely used because of their relative ease and inexpensiveness.  
Despite their popularity in clinical settings the use of creatinine based measures to assess renal 
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function is not without its shortcomings.  For one, it’s not the ideal marker because it is both 
filtered by the glomeruli and secreted by the renal tubules.  Creatinine is also produced by 
muscles thus apparent changes in GFR may be more of a reflection changes in of muscle mass in 
some individuals.  D espites its shortcomings, using a clearance creatinine based formula to 
estimate GFR is the most widely used clinical tool and has shown to be valid in those with renal 
impairment and may be useful in assessing renal function over time in these individual [72, 74, 
75].      
While no ideal endogenous markers of renal function have been identified, there are other 
markers of renal function, namely cystatin C, which are being investigated.  Cystatin C is a non-
glycosylated 13 kDa protein which is produced at a constant rate by all cells in the body [76].  
Since cystatin C production is not dependent on muscle mass or diet, many suggest it may be a 
better estimator of GFR than creatinine [77].  While, the results from some studies have shown 
that cystatin C is more accurate at determining renal dysfunction than creatinine, other studies 
have shown no difference between the two measures.  While cystatin C has been shown to be a 
better predictor of mortality than creatinine, there still are some questions as to whether it is  
relatively better at classifying CKD [78, 79].  As more studies are needed to determine the 
benefits of using cystatin C versus creatinine, some researcher have suggested that it is better to 
use both measures in equations to estimate GFR rather than either alone [80]. 
2.2 CHRONIC KIDNEY DISEASE 
The assessment of glomerular filtration is of immense importance because any deterioration in 
the kidney’s ability to perform filtration and other vital functions can have serious consequences.  
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Deterioration of kidney function is generally the result of damage to the nephrons, the functional 
units of the kidney.  Acute damage to the kidney can result from a variety of cause including 
immune disease, genetic disorders, infection, as well as trauma caused by injury or the use of 
some medications.  T he most common causes of renal deterioration are hypertension and 
diabetes, both of which will be discussed in more detail later in the literature review.  W hile 
some of these causes can be acute, chronic kidney disease occurs through gradual deterioration 
in function.   
The National Kidney Foundation has a classification system which indicates the stages of 
chronic kidney disease (see Table 2.1): 
Table 2.1 Chronic kidney disease classification 
 Glomerular Filtration Rate (mL/min/1.73 m2) 
Description 
Normal >90 
High risk (diabetes, 
hypertension, old age, positive 
family history, or a member of 
a high risk ethnic group) 
Stage 1 >90 with evidence of kidney damage Evidence of kidney damage (protein in urine) 
Stage 2 60 – 89 with evidence of kidney damage Kidney damage and mild decrease in renal function 
Stage 3 30 – 60 Moderate decrease in renal function 
Stage 4 15-29 Severe decrease in renal function 
Stage 5 <15 or dialysis Kidney Failure 
 
Normal renal function is defined as having a GFR >90 mL/min/1.73 m2 with no evidence 
of renal damage (albuminuria to creatinine ratio (ACR) <30 mg/g, no other urinary or radiologic 
evidence of renal damage).  Y ou may be considered at risk for CKD if you have other risk 
factors including diabetes, hypertension, older age, positive family history, or if you are a 
member of a high risk ethnic group.  Stage 1 CKD is defined as having a GFR between 90-130 
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mL/min/1.73 m2 + evidence of renal damage (A/C ratio >30 mg/g, most commonly).  S tage 2 
CKD is defined a having a GFR between 60-89 mL/min/1.73 m2 with evidence of renal damage.  
Stage 3 CKD is defined as having a GFR between 30-60 mL/min/1.73 m2.  Stage 3 can also be 
broke down further into early (3a) and late (3b) sub-categories [81]:  Stage 3a CKD is defined as 
having a GFR between 46-59 mL/min/1.73 m2 and Stage 3b is defined as having a GFR between 
30 - 45 mL/min/1.73 m2..  Stage 4 CKD is a severe decrease in kidney function defined as having 
a GFR between 15-29 mL/min/1.73m2.  Stage 5 CKD is also called renal failure and is defined 
as having a GFR below 15 mL/min/1.73m2.  If renal function falls to this level, the body needs 
help to keep up with the body’s filtration needs which comes in the form of dialysis or transplant. 
2.3 MARKERS OF RENAL DAMAGE 
As indicated by the National Kidney Foundation classification system, proteinuria is an early 
marker for renal damage even when GFR is normal.  The size selective properties of the kidney 
prevent larger molecules, such as proteins, from being filtered through the glomeruli.  E xcess 
protein in the urine is a marker of deterioration of this size selective barrier.  In normal adults, 
less than 130 m g of protein per day is found in urine [82].  Urinary protein levels above 130 
mg/day can be both a marker and a progression promoter.  Proteinuria can also promote CKD 
progression by stimulating protein reabsorption, which has pro-inflammatory and fibrogenic 
effects.  Proteinuria also stimulates the activation of the local renin angiotensin systems (RAS) 
which can lead to increases in glomerular pressure [83].    
Albumin is commonly used as a clinical manifestation of renal damage.  A lbumin 
excretion can either be determined in a t imed urinary specimen (e.g. 12 or 24 hrs) or in a spot 
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urine collection.  If the latter is used, the albumin is expressed per gram urinary creatinine to 
adjust for differences in urine concentration.  Microalbuminuria is defined as an ACR between 
30-300 mg/day (or 30-300 mg/g creatinine).  An ACR value above 300 mg/day is the definition 
of macroalbuminuria.  Studies have shown that albuminuria can serve as an early predictor of 
renal and cardiovascular events in individuals with diabetes, hypertension, and the general public 
[84-86].  This is of concern considering the high prevalence of albuminuria both in the US and 
worldwide, especially in individuals at high risk for CKD development.  T he Third National 
Health and Nutrition Examination survey study indicated that 28% of US adults with diabetes 
and 16% of individuals with hypertension had microalbuminuria compared to only 5.1% in 
healthy adults [87].  Microalbuminuria was also highly prevalent in older adults documented in 
nearly 20% of males and females over the age of 60, a group at increased risk for CKD.     
Reducing albuminuria is a proposed target to decrease cardiovascular and renal outcomes 
[88, 89].  T he Ramipril Efficacy in Nephropathy (REIN) study showed that high levels of 
proteinuria at baseline was associated with faster progression of CKD and subsequent reduction 
slowed the progression to ESRD in patients with non-diabetic nephropathy [90].  A  study by 
Araki et al demonstrated the beneficial effects of reducing urinary albumin in individuals with 
diabetes by controlling for traditional risk factors (blood pressure, glucose, etc.).  In this study, a 
reduction of albuminuria by 50% resulted in a decrease in renal or cardiovascular events by 
nearly 60% [91].  A dditional studies have confirmed the clinical importance of reducing 
albuminuria, mainly using pharmacological treatments directed at the renin-angiotensin system.  
Whether reducing albuminuria by other measures translates into decreased progression of kidney 
disease is not yet proven.  Lifestyle approaches such as increasing physical activity may 
potentially be effective in reducing urinary albumin.   
 18 
2.4 RISK FACTORS/CAUSE OF CKD 
2.4.1 Diabetes 
Diabetes is the leading cause of chronic kidney disease and ESRD.  CKD is present in 40% of 
individuals with a history of diabetes compared to 15% of individuals with no history of diabetes 
[10].  The United States Renal Data Systems also indicates that diabetes currently accounts for 
nearly half of the ESRD cases [21]. Studies have also shown that the progression of diabetic 
nephropathy is faster than non-diabetic nephropathy [92].  The course of CKD progression is 
similar among type 1 a nd type 2 diabetes patients, however, individuals with type 2 di abetes 
have traditionally been more likely to die of CVD prior to ESRD [92, 93].  With the worldwide 
prevalence of diabetes expected to reach well over 400 million by 2030, diabetic nephropathy is 
a major public health concern [94].     
Although having diabetes puts individuals at increased risk for CKD development, it’s 
important to note that not everyone who has diabetes develops diabetic nephropathy.  Diabetic 
nephropathy develops in 35-40 % of individuals with type 1 and type 2 diabetes and the 
progression of the disease is also highly variable [95, 96]. Studies have reported annual declines 
in GFR ranging from 2- 20 mL/min [24-26].  Several factors are related to this varied 
development and progression of diabetic nephropathy that have been observed.     
Blood pressure control has been identified as one of the key factors associated with 
development and faster progression of diabetic nephropathy [97].  A  study by Hovid et al 
showed that the annual decline in renal function was more than double the rate in individuals 
with hypertension compared to individuals who were normotensive.  The study also showed that 
achieving blood pressure control through anti-hypertensive treatment slowed the progression of 
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renal decline [98].  In addition to strict blood pressure control, tight glucose control has been 
identified as an important factor in the development of diabetic nephropathy [51, 99].  The 
Diabetes Control and Complications Trial and Epidemiology of Diabetes of Interventions and 
Complications (DCCT/EDIC) study showed that intensive glucose control decreased the risk of 
cardiovascular disease and lowered the risk for retinopathy and nephropathy in individuals with 
type 1 diabetes [100].  The benefit of glucose control in individuals with type 2 diabetes is less 
clear.  S ome studies have found that intensity of glucose control provided no e xtra benefit in 
reducing cardiovascular outcomes [101].  In the Steno-2 study, treatment of hypertension and 
dyslipidemia were found to be more important than glucose control in individuals with type 2 
diabetes [102].  The data on later stages of kidney disease are still sparse and future studies are 
needed to investigate the benefits of glucose control in individuals with type 2 diabetes.   
2.4.2 Hypertension  
Hypertension is the second leading cause of CKD.  Data from NHANES have shown that 16% of 
adults in the United States with hypertension have CKD compared to 5.1% of normotensive 
adults.  B lood pressure control in individuals with CKD is often poor [103].  A  study by 
Plantinga et al showed that 70% of individuals with CKD from 1999-2006 in the United States 
have uncontrolled blood pressures [104]. These numbers are alarming considering the strong 
evidence that poor blood pressure control is associated with rapid progression of the disease 
[105, 106].  E ven marginal increases in blood pressure can result in worse outcome for 
individuals with CKD.  A  study by Hsu et al showed that even among those with pre-
hypertension (systolic blood pressure of 130 to 139 mm Hg and diastolic blood pressure <90 mm 
Hg or diastolic blood pressure of 85 to 89 mm Hg and systolic blood pressure <140 mm Hg), 
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there was a near two fold increase in risk of ESRD development compared to those with normal 
blood pressure[107].  A study by Bakris et al also showed that every increase of 10 mmHg in 
baseline systolic blood pressure resulted in an increase risk of ESRD or death by 6.7% [29].  
With the increasing risk for adverse outcomes being experienced with changes in blood pressure, 
even in the “normal” range, hypertensive therapy is of utmost importance in CKD management. 
Recognizing the importance of aggressive treatment of hypertension in patients with 
CKD, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure has recommended blood pressure goals of 130/80 mmHg.  Pharmacological 
therapies such as angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocks 
(ARB) have been used to treat hypertension [108].  Several studies have shown that anti-
hypertensive therapy slows the progression of kidney disease [109, 110].  The benefit of blood 
pressure reduction may be especially important in individuals who are obese. A 20-year follow-
up study in Norway showed that obese individuals with pre-hypertension had nearly three times 
the risk for adverse outcomes compared to individuals with normal blood pressure.  There was 
no increase risk for adverse events in individuals who were not obese [111].  B lood pressure 
treatments through ACE inhibitors or ARB’s have the added benefit of reducing proteinuria in 
addition to lower blood pressure [106] [112].    
2.4.3 Race/ethnicity  
Ethnic minorities carry a disproportionate burden of CKD and the progression to ESRD.  In 
2004, it was reported that African Americans have the highest incidence of ESRD, which 
develops at a rate five times that of whites  [113].  Although African Americans on dialysis may 
have a survival advantage over to whites on dialysis, they are more likely to die at earlier stages 
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of the disease compared to whites [114].  Other ethnic minorities including American Indians, 
Alaskan Natives, Asians, Pacific Islanders, and Hispanic also experience disparities in the 
prevalence of CKD [115, 116].  African Americans, Native Americans, and Asian/Pacific 
Islanders make up 29.6%, 1.6%, and 3.2% of the ESRD population despite making up smaller 
percentages of the general population [117, 118]. There has been an increasing disparity in the 
incidence of ESRD in African Americans compared to whites over the last twenty five years.  A 
disparity in ESRD incidence is also seen in American Indians compared to white, however, that 
disparity has been decreasing in recent years. 
One possible explanation for the decreasing incidence of ESRD in American Indians may 
be better diabetes management [14, 119].  Another explanation may be that American Indians are 
experiencing an increase in another chronic disease, such as heart disease that may be occurring 
prior to developing ESRD.  Analysis of data from the Strong Heart Study by Howard et al. has 
shown that rates of coronary heart disease was nearly twice as high in American Indian 
participations of the SHS compared to individuals from a cohort of white and black participants 
(Atherosclerosis Risk in Communities Study) [120].  A report for the CDC in 2001 indicated that 
36% of all  deaths from heart disease in American Indians in the US were pre-mature (<65 years 
of age) [121].  Lastly, there may be an increase in the number of individuals self-reporting 
American Indian as their ethnicity in the later years which may bias the sample, making them 
their risk appear more similar to whites .   
Addressing the ethnic disparities of CKD was an objective of Healthy People 2010 and 
will likely continue to be a goal in the future. Reasons for the disparities in CKD are multi-
factorial including social, biological, and institutional factors. 
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One factor which is likely responsible for the excess prevalence of CKD in minority 
populations is the higher prevalence of diabetes in those minority groups.  The prevalence of 
diabetes is nearly two times higher among African American, Mexican American, and Native 
Americans compared to whites (CDC).  Management of diabetes in minority populations is also 
poor, which leads to a higher frequency of diabetic complications including CKD.   Studies have 
indicated that minorities are more likely to have uncontrolled blood pressure and poorly 
controlled glucose levels compared to whites [103, 122-126].  Reasons for poor diabetes 
management and subsequent complications in minorities may be related to socio-economic and 
educational factors [127, 128]. There may also be some biological factors which influence the 
progression of diabetic nephropathy.  A study by Goldschmid indicated that African Americans 
have a higher prevalence of microalbuminuria within 1 year of diabetes diagnosis independent of 
glucose control [129].     
Hypertension, the second leading cause of ESRD, is also more prevalent in African 
Americans compared to whites.  While lifestyle factors are important, increased salt sensitivity in 
African Americans may be an important biological factor [130].  S tudies have shown that 
increases in salt intake raises blood pressure more in African Americans compared to whites 
[130].  The results of the DASH study indicated a greater drop in blood pressure with sodium 
restriction in African Americans [131].       
In addition to the biological factors which lead to disparities of CKD, there are also 
social/behavioral factors which come into play.  CKD progresses silently in early stages and 
there is a general lack of awareness both worldwide as well as in minority communities.  The 
Jackson Heart Study was an observational study of African Americans in three Mississippi 
communities which assessed kidney disease through eGFR and the presence of albuminuria.  The 
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study documented that only 16% of the individuals with CKD were aware of their condition.  
Even among those in stages 4-5 CKD, awareness was only around 65%, which was lower than 
their awareness of diabetes or hypertension [132].   A study by Waterman et al conducted a study 
of African Americans in 7 s tates across the United States and showed that over 40% of the 
sampled population had CKD, but less than 3% viewed it as a top concern [133].  The lack of 
concern and awareness about CKD may lead to African Americans missing opportunities for 
detection and subsequent medical intervention at earlier stages of the disease. 
Lifestyle factors such as obesity and physical inactivity also influence disparities of CKD 
among ethnic minorities.  There are higher rates of obesity among ethnic minorities, particularly 
African American females and Native Americans compared to whites.  Also, among African 
American females and Native Americans, self reported physical inactivity has consistently been 
high in national surveillance studies. 
2.4.4 Age 
Normal renal function in adults is typically around 125 mL/min/1.73m2.  As we age, glomerular 
filtration steadily decreases.  A fter the age of 40, GFR decreases about 8 m L/min/1.73m2 a 
decade.  This perpetual decline in GFR places older adults at greater risk for CKD development 
[134-136].  T he prevalence of CKD is greater in older adults with approximately 40% of 
individuals >65 years of age having CKD in the United States.  These results are consistent with 
rates of CKD in older adults around the world.  Older adults with CKD experience an increase 
risk for morbidity and mortality (USRDS).  With the aging of our population, CKD will continue 
to pose a problem.     
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2.4.5 Gender 
Many studies have indicated that male gender is associated with faster progression of renal 
disease.  Males, more frequently than females, develop ESRD at all ages [10].  The MDRD study 
also showed that males have more rapid decline of GFR than females, which was explained by 
higher urinary protein excretion, mean arterial pressure, and HDL cholesterol at baseline [137].   
Other studies have indicated that genetic differences between males and females may explain the 
differences in renal outcomes.  In individuals with diabetes, females have been shown to have 
better renal endothelial function than males, which may influence progression of diabetic 
nephropathy [138].  In animal models, male mesangial cells produced greater pro-inflammatory 
activity compared to females [139].     
2.4.6 Dyslipidemia 
Individuals with CKD are at increased risk for adverse CVD outcomes.  Part of that increased 
risk may be due to the high prevalence of traditional risk factors for CVD, such as dyslipidemia.  
An abnormal lipid profile including elevated triglycerides, low density LDL particles, very low 
density lipoproteins (VLDL), and low levels of HDL cholesterol, is both a promoter of and 
consequence of CKD [140].  Secondary dyslipidemia in CKD patients is the result of 
abnormalities in key proteins that regulate lipid metabolism [141].  The reduced expression of 
lipoprotein lipase by skeletal muscle and adipose tissue leads in reduced plasma clearance of 
VLDL and chylomicrons which results in elevated triglyceride levels[142].   There is also 
increased synthesis and decreased catabolism of LDL by the liver when CKD is accompanied by 
albuminuria [143, 144].  Increased oxidative stress and inflammation are also consequences of 
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abnormal lipid levels leading to damage to endothelial cells, increased atherosclerosis, and faster 
progression of the CKD [145].  The use of statins may not only reduce lipid levels, but may also 
reduce inflammation and slow progression of the CKD.     
It is important to note that the lipid profile of a CKD patient will vary depending on the 
stage of the disease and level of proteinuria.  In individuals without proteinuria, LDL is typically 
normal or mildly elevated.  There is an increase in triglycerides and decrease in HDL.  In 
proteinuric patients, LDL levels can be very high.  Reverse epidemiology between total 
cholesterol and mortality has been document in dialysis patients.  Multiple observational studies 
have shown that in patients on di alysis, those with hypocholesterolemia (<100 mg/dl) had an 
increase risk of mortality compared to individuals with high cholesterol (200 – 250 mg/dl) [146, 
147].  H ypocholesterolemia in dialysis patients may be a marker for inflammation since the 
hypocholesterolemia is associated with elevated levels of C-Reactive Protein (CRP) and in the 
subset of individuals on dialysis who do not have markers of inflammation, the usual pattern of 
elevated cholesterol being associated with morality is seen [148].   
2.4.7 Smoking 
Smoking status is a known risk factor for CKD.  A study by Hallan et al showed that current 
smokers had a relative risk of 1.52 for having CKD in the NHANES population [40].  A study by 
Shankar et al showed that former and current smokers had a 1.12 and 1.97 odds of developing 
CKD over those who never smoked [149].  This risk was increased 5 fold in those with heavy 
alcohol consumption.  Smoking has also been shown to be a significant predictor of advanced 
stage CKD.  In a study by Yamagata et al, current smokers had a 1.13 and 1.16 higher risk of 
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developing CKD (Stage 3 or higher) compared to non-smokers in men and women respectively 
[150].   
2.4.8 Nutrition 
Dietary factors such as reducing the intake of salt, alcohol, and animal proteins may be important 
for preserving renal health.   Salt intake may be directly and indirectly linked to renal function.  
Indirectly, salt intake has been shown to be related to hypertension [151].  The DASH Sodium 
trial showed that reducing sodium intake decreased blood pressure in individuals with and 
without hypertension.  A few studies have also highlighted direct links between salt intake and 
renal health [152, 153].  I n animal models, high salt diets lead to increased renal fibrosis in 
normotensive and hypertensive rats [154].      
Alcohol intake may be another important dietary factor for preserving renal health.  
While moderate alcohol consumption may have beneficial effects, such as increased HDL 
cholesterol, excessive alcohol intake may lead to renal damage. The AusDiab study reported an 
increase risk for albuminuria in individuals who self reported heavy alcohol consumption during 
the five years of study follow-up [155].  In addition, alcohol intake is a potent risk factor for 
hypertension.   
In individuals with pre-dialysis CKD, reducing animal protein intake may slow the 
progression of CKD.  The MDRD study examined the effects of a two-three year protein 
restricted diet and the risk of developing renal failure or all cause mortality.  After six years of 
follow-up there was no benefit of protein restriction.  A significant limitation of the study was 
the lack of dietary information during follow-up.   A meta-analysis by Pedrini et al examined the 
relationship between dietary protein intake and renal function in diabetic and non-diabetic CKD 
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[156].  In individuals with non-diabetic CKD, a low protein diet was associated with a reduced 
risk for renal failure and death compared to individuals with a normal protein diet.  In individuals 
with diabetic CKD, a low protein diet was associated with a reduced risk for renal function 
declines. 
2.4.9 Other 
Other causes of kidney disease include inflammation, genetic disorders, auto-immune disease, 
kidney obstructions, and birth defects.  G lomerulonephritis is a group of disease that cause 
inflammation and is the third most common cause of CKD.  Chronic inflammation can also be 
caused by repeated urinary tract infections.  Genetic diseases such as polycystic kidney disease 
also cause damage to the kidney by the formation of large cysts.  These cysts cause an increase 




3.0  CHAPTER 3 
3.1 PHYSICAL ACTIVITY IN EPIDEMIOLOGICAL STUDIES 
Physical activity is any bodily movement that results in energy expenditure, which encompasses 
structured planned movements such as exercise as well as unstructured movements [157].  
Physical activity occurs in four major domains: leisure, occupational, household, and 
transportation.  T he various domains and types of physical activity add to the complexity of 
activity assessment, especially in the free living environment [158].   
There are also many dimensions of physical activity including frequency, duration and 
intensity which further complicates activity assessment.  Frequency is a measure of how often 
physical activities are performed over specific time frames (e.g. how many times per month?).  
Duration of physical activity refers to the amount of time spent in a bout of an activity each time 
it is performed (minutes, hours, days, etc.).  Intensity of physical activity refers to the level of 
effort or physiological demand that an activity requires [159].  In many epidemiological studies, 
metabolic equivalents (METs) are used to express activities as intensity weighted values (1 MET 
= resting metabolic rate).  Light activities, such as sitting or standing, have a MET level of less 
than three. Activities of moderate intensity, such as brisk walking, are said to have a MET value 
between three and six.  V igorous physical activities, such as running, have a MET of six or 
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greater.  Physical activity can occur along a spectrum of intensities which have important 
implications for which assessment tool is most appropriate (Figure 1).      
 
 
Figure 3-1 Physical activity spectrum  
3.1.1 Subjective Assessment 
Subjective measures are the most frequently used method of assessing physical activity in free-
living individuals.  Subjective methods can include physical activity records or logs, which 
require individuals to record every activity done over a predetermined period of observation.  
However, these methods are utilized less frequently in large populations and community-based 
studies due to the high associated staff and participant burden with completing and calculating 
summary estimates.  A s such, physical activity questionnaires will likely continue to be the 
primary method used to estimate physical activity levels in research studies due to their low cost 
and relative ease of administration.     
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Physical activity questionnaires vary in their complexity, physical activity domain (e.g., 
leisure, occupational, transportation, activities of daily living), recall time frame (e.g., past 24-
hours, week, month, year), mode of administration (i.e., interviewer- vs. self-administered), and 
characteristics of the targeted population (i.e., older adults, women, children).  Physical activity 
questionnaires may also vary by study design, with some developed to use for surveillance while 
others are sensitive to behavior change for use in intervention studies.  U nderstanding the 
intended use and psychometric properties (i.e., test-retest reliability, validity, and sensitivity) of a 
physical activity questionnaire will help researchers identify which questionnaire is most 
appropriate for the study population being investigated.  Further use of an appropriate measure 
will improve the overall precision of the physical activity estimate and enhance the ability to 
establish significant relationships between physical activity and the health-related outcomes of 
interest.  It is important to note that failure to account for the psychometric properties of a 
physical activity questionnaire may increase the risk of non-differential misclassification which 
can weaken or eliminate association between physical activity and health outcomes.   
Questionnaires vary in their complexity from a single global question about general 
physical activity level (i.e., low, moderate, and high activity) to activity-specific questionnaires 
that inquire about physical activity done over an individual’s lifetime.  A simple questionnaire 
such as the Lipid Research Clinics physical activity questionnaire is one example of a global 
measure.  With global questionnaires, participants are asked questions such as, “Thinking about 
the things you do at work, how would you rate yourself as to the amount of physical activity you 
get compared with others of your age and sex?”  Global queries such as these can be used to 
crudely group individuals by their activity or inactivity status.  O n the other end of the 
complexity spectrum, activity-specific questionnaires or historical questionnaires such as the 
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Historical version of the Modifiable Activity Questionnaire (MAQ) ask about participation (i.e., 
frequency and duration) in leisure activities over specific periods during an individual’s lifetime.   
In general, physical activity can be classified into one of four domains (i.e., leisure, 
occupation, transportation, and household activities).  Thus, physical activity questionnaires may 
differ in the types of activities they try to capture.  S ince it is  imperative to capture accurate 
information on the types of activities that elicit the greatest energy expenditure in the targeted 
population, you need to find a physical activity questionnaire that measures all key domains.   
One study which highlights the importance of assessing all of the key domains of 
physical activity was a study by Kriska et al. which examined the association between physical 
activity, assessed with the modifiable activity questionnaire (MAQ), and serum insulin levels in 
two different populations (Pima Indians in Arizona and individuals from the island nation of 
Mauritius).  T he MAQ assesses activities during leisure and occupation.  F or Arizona Pima 
Indians, the majority of their physical activity was accumulated during leisure while individuals 
in Mauritius accumulated over 90% of their activity from occupational activities [160].  If the 
MAQ had not assessed leisure time physical activity, it’s likely the results of study would not 
have impacted in Pima Indian data.  However, failure to assess occupation activity in individuals 
from Mauritius would have missed most of the activity performed in this population.       
While questionnaires accurately measure activities of moderate- to vigorous- intensity, 
they are less accurate with light intensity activities, such as light cleaning.  M any researchers 
only measure physical activity during leisure because there tends to be little between person 
variation in occupation, transportation, and household activities.  However, the assumption of 
homogeneity of activity outside of leisure (occupation, transportation, and household) may not 
be valid in all populations, with Mauritius as a good example of this. 
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Questionnaires also vary in the time frame of interest ranging from past day to 
participation in physical activity across the lifespan.  Short term questionnaires which ask about 
activity performed in the past week or day provide a good estimate of an individual’s current 
activity level; however, they may also be subject to issues of seasonality and changes in health 
status.  Physical activity questionnaires that utilize a shorter recall time frame may also be 
repeated a number of times throughout the year to provide an estimate of physical activity done 
over a longer period of time (i.e., four measures spaced three months apart would provide an 
estimate of physical activity done over the past year).   Physical activity questionnaires may also 
ask questions about participation in activity in the past year or lifetime to provide a more general 
estimate of one’s physical activity level.  The estimates generated from these physical activity 
questionnaires may relate better with chronic conditions (i.e., obesity, cardiovascular disease, 
type 2 diabetes mellitus) which may take many years to develop.    
As stated previously, physical activities can occur along a spectrum of intensity.  
Questionnaires may ask participants about the activities they perform and then compare those 
activities to a standardized intensity scoring compendium.  C ompendiums of physical activity 
intensity have been published which code various activities by their respective intensity level 
[161].  Light activities, such as sitting or standing, have a MET level of less than three. Activities 
of moderate intensity, such as brisk walking, are said to have a MET value between three and 
six.  V igorous physical activities, such as running, have a MET of six or greater.  S ince 
questionnaires are more accurate at assessing activities at the higher end of the physical activity 
intensity spectrum, many avoid querying activities at the lower end of the intensity spectrum. 
There are a few questionnaires however, which do attempt to assess activities of low intensity 
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[162, 163].  It is unlikely that the inclusion of low intensity activities improves physical activity 
assessment in questionnaires [164].    
Questionnaires may be either self- or interviewer-administered.  Interview-administered 
questionnaires such as the MAQ require an interviewer to go through the questionnaires with the 
participant.  It is important to train interviewers on the proper method of administering 
interviewer-administered questionnaires to improve the precision of the physical activity 
estimate.  S elf-administered questionnaires are completed by the participant and can either be 
done in-person (i.e., Women’s Health Initiative Physical Activity Questionnaire) or administered 
via the mail (i.e., Nurses’ Health Study Physical Activity Questionnaire) [165].  If using a self-
administered questionnaire it is  important for the study staff to review the physical activity 
questionnaire (PAQ) thoroughly to make sure all items are completed properly.   
The population of interest may also be an important question when deciding which 
questionnaire to use.  Questionnaires may be designed for specific ages, gender, ethnicities, and 
disease.  T here are specific questionnaires designed for elderly populations, such as the Yale 
Physical Activity Survey, which ask questions about the physical activities that are most 
commonly performed by older adults (e.g., walking, gardening) [166, 167].  It is important to 
take these population characteristics into account in order to select the most appropriate 
assessment tool that has been shown to be valid and reliable in that particular population.     A 
questionnaire that was developed for use in one population or setting (i.e., surveillance vs. 
intervention) may not be appropriate to use in another. 
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3.1.2 Objective Assessment 
Physical activity assessed objectively addresses some of the short-comings of subjective 
assessment.  One of the main advantages of objective assessment is that it doesn’t rely on recall 
which may be a source of bias in subjective assessment [159]. Some objective measures of 
physical activity also perform better at assessing components of physical activity which are not 
accurately assessed by questionnaires such as activities which occur at the lower end of the 
intensity spectrum or activities which are spontaneous/unstructured [168].  There are a variety of 
objective assessment tools available including pedometers and accelerometers which are 
described in more detail elsewhere [159].  A ccelerometers are objective measures of physical 
activity which are frequently used to assess free living physical activity [169].  Physical activity 
was assessed via accelerometer in both manuscript 1 a nd manuscript 2 a nd will be described 
below in more detail. 
Accelerometers are movement monitors that have the ability to not only capture 
movement, but also the intensity of that movement in one or more planes [170]. They are 
typically attached to a person’s waist with a belt clip; however, some monitors can also be worn 
on the back, wrist, ankle, or even a shoe [171].  Although here is no one true “gold standard”, 
accelerometers are considered to be one of the best available methods for assessing free living 
physical activity levels and are often used to validate the much simpler, less expensive 
pedometer and physical activity questionnaires [172]. 
Accelerometers operate by measuring acceleration along a given axis, using a number of 
technologies including piezo–electric, micro–mechanical springs, and changes in capacitance 
[173]. Multiple axis measurements can also be bundled into a single monitor, allowing 
movement in multiple planes to be captured. The major function of accelerometers is that the 
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sensor converts movements into electrical signals (counts) that are proportional to the muscular 
force producing motion [174]. These counts are summed over a specified period of time (epoch) 
and stored.   
Intensity of physical activity has most often been determined by comparing the counts 
accumulated during various activities to measured oxygen consumption.  Regression equations 
are then used to develop prediction equations to calculate intensity specific count cut points.  
These cut points represent a range of accelerometer counts which correspond to light, moderate, 
and vigorous physical activity.  Figure 2 provides an example of the metabolic cost of various 
activities and the counts associated with that metabolic cost from a calibration study by Freedson 
et al [174].  Using the Freedson established cut points, activities of light (1-3 METs), moderate 
(3-6 METs), and vigorous intensity (>6 METs) are associated with cut points of 100-1951, 1952-




Figure 3-2 Accelerometer Cut Points 
 
Although accelerometers have shown promise for assessing physical activity in free 
living conditions, they are not without their limitations.  Accelerometers were design to assess 
simple ambulatory activities such as walking and running.  One of the major limitations of 
accelerometers, when worn on the hip, is their limited ability to accurately assess more complex 
lifestyle oriented movement such as those using the upper extremities  [168].  The narrow ability 
to assess more complex movements limit th e accelerometers ability to measure activities that 
may be common in many individuals’ daily lives.  As result, there are a variety of intensity cut 
points derived from various calibration studies which differ on t he range of activity intensity 
(light, moderate, and vigorous) as well as the types of physical activities (lifestyle oriented 
activity, walking, running, etc.) used to develop prediction equations  [174-178].    Results from 
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these various calibration studies reveal the need to develop regression equations from a full 
spectrum of physical activity intensity from a variety of activities [168].  Accelerometers are also 
unable to measure activities such swimming, and underestimate energy expenditure in activities 
such as weight lifting and cycling.  One remedy may be to have participants complete a activity 
log during times the monitor is not worn, such as swimming, or when performing activities such 
as cycling or weight lifting.  Correction equations may then be used to adjust the accelerometer 
data [168].  
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4.0  CHAPTER 4 
4.1 PHYSICAL ACTIVITY AND CHRONIC KIDNEY DISEASE 
Physical activity has been shown to prevent and/or delay the onset of many chronic conditions 
such as diabetes and cardiovascular disease.  The vast amount of evidence for the benefits of a 
healthy lifestyle was discussed in the 1996 Surgeon General’s Report on Physical Activity and 
Health which recommended that all adults should achieve at least 150 m inutes of physical 
activity per week [179].  S ince this report, increasing levels of physical activity and reducing 
levels of inactivity continue to be health goals for our nation, as documented by Healthy People 
2010 [36].   
Despite these national goals and recommendations, physical activity levels are still low 
for many Americans, placing them at risk for developing chronic disease such as CKD and 
subsequent complications for the disease.  A survey of nephrologists at the 2003 World Congress 
of Nephrology indicated that 95% of the nephrologists surveyed believe that a sedentary lifestyle 
was an important risk factor in individuals with CKD [35].  Individuals with ESRD especially, 
are at greater risk for diminished functional capacity and quality of life when leading a sedentary 
lifestyle [43, 180].  In the Wave 2 of the Dialysis Morbidity and Mortality Study, less than half 
of the study participants on dialysis engaged in physical activities more than once per week and 
75% reported limitations in their ability to engage in vigorous physical activity [41].  T hese 
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reported limitations in their exercise capacity were associated with an increase risk for mortality 
in this population [42, 43].  Even though exercise capacity is diminished in individuals with 
ESRD, it’s important to note that exercise training has been shown to improve aerobic capacity, 
physical function, and health related quality of life in these individuals [45-49, 181].      
The benefits of physical activity go beyond improving physical function in individuals 
with ESRD.  There is also some evidence to suggest that physical activity can also be effective at 
preventing the development of CKD [153].  The benefits of physical activity in preserving renal 
health may be related to physical activity’s affect on important risk factors for CKD.  Physical 
activity, along with dietary changes and weight loss, has been shown to prevent and or delay the 
onset of many chronic conditions such as diabetes, the leading cause of CKD [50].  In addition to 
preventing the development of diabetes in high risk individuals, physical activity may help 
individuals with diabetes better manage their diabetes through improved glucose control which is 
important for preventing diabetic complications such as CKD [51].  B lood pressure control is 
also key, especially among individuals with diabetes, in preventing CKD development and 
progression [52].  Physical activity has been shown to reduce blood pressure, especially in 
individuals with hypertension [53, 182, 183] .  Improving lipid profiles and reducing levels of 
inflammation are also potentially important factors in preventing CKD progression, and may be 
beneficially impacted upon by physical activity [54, 55, 184]. 
4.1.1 Physical Activity and Diabetes 
Diabetes is the leading cause of CKD and ESRD.  T he increased risk for CKD and other 
macrovascular and microvascular complications that diabetes imposes has prompted many health 
care professionals to investigate ways to prevent diabetes development.  In addition to preventing 
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the development of diabetes in individuals at high risk, proper diabetes management is crucial 
for preventing complications of the disease.  Lifestyle approaches which include increasing 
physical activity levels have be used in both the prevention of diabetes development as well as 
proper management of the disease.   
There have been numerous studies which documented the benefits of lifestyle 
modifications, which includes physical activity, for preventing and/or delaying the onset of 
diabetes in high risk individuals.   One of the first studies to show the benefits of lifestyle on 
reducing diabetes risk was the Malmo feasibility study which examined the effects of physical 
activity and diet on the risk of type 2 di abetes development in nearly 7000 males aged 47-49 
from Malmo, Sweden.  After six years of follow-up, the accumulated diabetes incidence was 
10.6% and 28.6% in the intervention and control group respectively [185].  Although the major 
limitation of the study is that individuals were not randomly assigned to their intervention 
groups, it did support a beneficial role of lifestyle on diabetes prevention.  
Since the Malmo trial, numerous other studies have shown the effectiveness of lifestyle in 
preventing diabetes development.  One of the most successful trials, the US Diabetes Prevention 
Program (DPP), also examined the association between lifestyle (diet, exercise, and weight loss) 
and diabetes development in individuals at high risk for diabetes.  C ompared to the control 
group, the lifestyle arm of the intervention resulted in a 58% reduction in diabetes incidence 
[186].  The study also showed that achieving the lifestyle goals reduced diabetes risk across all 
gender, age, and racial groups regardless of BMI.  While the study wasn’t powered to test the 
association between physical activity and diabetes risk independently, it is important to note that 
among individuals who didn’t meet their weight loss goal, those who did meet their physical 
activity goal had a 44% lower risk of diabetes development [187]. 
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In individuals who have already converted to diabetes, lifestyle modifications may be no 
less important because of their potential to reduce the risk for subsequent complications [188].  
The importance of metabolic control (glycemic control and insulin sensitivity) for reducing the 
risk for diabetes complications has been demonstrated in numerous studies of both type 1 and 
type 2 diabetes patients [189-192].  Participating in regular physical activity may be one strategy 
for improving metabolic control [193].  A meta-analysis of clinical controlled trials by Boule et 
al examined the association between exercise and glycemic control in type 2 diabetes patients.  
The analysis included 14 trials with interventions ranging between eight and fifty two weeks.  
The exercise interventions ranged from 3-6 days per week with an average duration of 52 
minutes.  T he analysis indicated a 0.66% reduction in HbA1c levels from baseline in the 
intervention group versus the controls (p<0.01) [194].  A more recent meta-analysis examining 
the association between exercise and glycemic control in type 2 diabetes patients by Thomas et 
al produced similar results showing a reduction of 0.6% in HbA1c from baseline in the 
intervention versus the control group [195].  Both of these meta-analysis showed that the results 
were independent of weight loss.   
4.1.2 Physical Activity and Blood Pressure 
Hypertension is the second leading cause of CKD and is often a comorbid condition in patients 
with diabetes.   The prevalence of hypertension in individuals with diabetes is as high as 60% 
and the co-occurrence of these two conditions are associated with faster progression of CKD 
[182, 196].  In addition to metabolic control, reducing hypertension is critical for reducing the 
risk of CKD development and progression among individuals with diabetes [197].  Even among 
individuals without hypertension, high normal blood pressures (systolic 130-139 mm Hg or 
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diastolic 85-89 mm Hg) are associated with an increased risk for cardiovascular events in 
individuals with or without CKD [198, 199].  The Joint National Committee on P revention, 
Detection, Evaluation, and Treatment of High Blood Pressure recommends an aggressive goal 
for blood pressure control (systolic <130 mm Hg and diastolic <85 mm Hg) in individuals with 
diabetes and other high risk groups [200].   
Effective treatment of hypertension, most often pharmacologically, is associated with 
slowing the progression of CKD [95, 98].  In addition to pharmacological treatments, physical 
activity is recognized as an effective treatment of hypertension by the American College of 
Sports Medicine and the American Heart Association [200-203].   A meta-analysis of 53 
randomized controlled trials showed that increasing physical activity levels was associated with 
an approximate decrease in systolic blood pressure of 4 mm Hg [204].  T he blood pressure 
lowering effects of physical activity was highest among individuals with hypertension and in 
African Americans (5 mm Hg and 11 mm Hg respectively).  A  more recent meta-analysis 
confirmed these results indicating that physical activity can lead to reductions in systolic blood 
pressure of 3 mm Hg, with a greater effect in hypertensive individuals (-6.9 mm Hg) [205].  Few 
studies however have examined the effects of physical activity on l owering blood pressure in 
individuals with diabetes [182].  One study of patients with type 2 diabetes by Schneider et al. 
did show that one year of moderately intense exercise, three to four days per week, had a blood 
pressure lowering effect [206].   
The results of these studies demonstrate the benefits of exercise in reducing blood 
pressure, especially in individuals with hypertension.  Regular participation in physical activities, 
along with appropriate pharmaceutical treatments, should be a part of a strategy to slow the 
progression and occurrence of CKD.   
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4.1.3 Physical Activity and Lipids 
Individuals with CKD have abnormal lipid profiles which may be cause and consequence of the 
disease [207].  The most common manifestations of lipid abnormalities are elevated triglycerides 
and lipoprotein (a), and reduced HDL cholesterol levels.  Results from both animal and human 
studies have shown that elevated triglycerides and reduced HDL cholesterol levels are associated 
with faster progression of CKD [208, 209].  Although most of the studies in humans have been 
small, meta-analysis has documented the benefits of reducing lipid levels on r enal outcomes.  
Reducing lipid levels slows the decline in GFR and decreases proteinuria, as document by a 
meta-analysis by Fried et al [210].  A nother meta-analysis by Sandhu similarly showed that 
reducing lipids slowed the progression of CKD and reduced proteinuria, however, the results 
were not significant in individuals with diabetic or hypertensive nephropathy [211].   
While statin therapy has been shown to be effective in reducing lipid levels, lifestyle 
modification may also have therapeutic benefits.  Numerous studies have indicated that exercise 
can improve both triglyceride and HDL levels.  Improvement in triglycerides and HDL are more 
pronounced in individuals with elevated baseline lines but also documented in individuals with 
low levels [212, 213].  While exercise can affect triglyceride and HDL levels acutely, chronic 
exercise, lasting at least 12 weeks, is what is most often  required to induce improvements in 
these factors [214-216].  A study by Goldberg et al showed that twelve months of endurance 
training led to a 23% reduction in triglycerides and a 21% increase in HDL cholesterol levels in 
hemodialysis patients [217]. A study of non-dialysis CKD patients showed that cardiac 
rehabilitation programming, which included exercise, led to reductions in triglycerides, total and 
LDL cholesterol levels [45].  O verall, the literature supports the idea that chronic physical 
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activity can cause reductions in triglyceride levels between 4-37% and increases in HDL can 
between 4-18% [184]. 
The relationship between kidney function with total cholesterol and LDL cholesterol is 
more complex.  In both hemodialysis and non-dialysis CKD, LDL levels may be within the 
normal the range [218].  H owever, when protein is present in the urine, LDL and total 
cholesterol levels may be elevated [218].   The relationship between total cholesterol, LDL, and 
physical activity is also less clear.  Some studies have shown that no relationship exist between 
physical activity and total cholesterol, however, a few studies have shown an inverse relationship 
[219-221].  The relationship between physical activity and total cholesterol may be mediated by 
weight loss [222].  There have also been conflicting reports on the effects of physical activity on 
LDL, which also may be mediated by weight loss [184, 223, 224].  
4.1.4 Physical Activity and Inflammation 
Cytokines may be classified as either pro- or anti-inflammatory, both of which having important 
roles in vascular health [225].  Under conditions of chronic disease such as CKD, there is often 
an imbalance in the circulating levels of cytokines, with pro-inflammatory cytokines levels being 
greater.  This imbalance that is seen in individuals with CKD leads to faster progression of the 
disease, increased cardiovascular risk, and early mortality [226, 227].  Reducing the levels of 
inflammation has been shown to preserve renal function [226, 228, 229].   
Physical activity may affect inflammation by both increasing the levels anti-inflammatory 
cytokines and reducing the levels of pro-inflammatory cytokines.  A study of 28 patients with 
coronary heart disease by Goldhammer et al, showed that 12 w eeks of high intensity aerobic 
training reduced levels of pro-inflammatory cytokines and increased levels of anti-inflammatory 
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cytokines [230].  A  study by Smith et al showed similar results in patients at high risk for 
developing heart disease.  In this study, individuals received a six month tailored exercise 
program.  O verall, pro-inflammatory cytokines (CRP, TNF-α, IL-6, and interferon gamma) 
decreased by 58% and anti-inflammatory cytokines (IL-10, IL-4, and TGF-β1)  increased by 
35% [231].  T he Finnish Diabetes Prevention Program examined the effects of the individual 
components of the lifestyle modification (diet, weight loss, physical activity) on CRP and IL-6.  
Leisure time physical activity of moderate intensity was related to reductions in both CRP and 
IL-6 independent of BMI [232].  While few studies examined the association between physical 
activity and inflammation in patients with CKD, the Progressive Exercise for Anabolism in 
Kidney Disease documented a decrease in CRP levels after 12 weeks of resistance training in 
patients on hemodialysis [233]. 
4.1.5 Physical Activity and Albuminuria 
In addition to being related to risk factors for CKD, physical activity is also related to markers of 
renal damage such as albuminuria.  Acutely, physical activity can cause an increase in albumin 
in the urine and is associated with the intensity of the activity [234].  T his increase in 
albuminuria after intense physical activity is believed to have no l ong term consequences and 
albuminuria levels should return to normal with 24 to 48 hours [235].  While physical activity 
increases albuminuria acutely, long-term engagement in aerobic physical activities of moderate 
intensity may decrease levels of albuminuria through reduction in endothelial dysfunction [225, 
236, 237].  A study of 372 individuals with type 2 diabetes by Calle-Pascual et al showed that 
albuminuria was prevalent in approximately 60% in individuals whose physical activity energy 
expenditure was less than 500 kcal/wk compared to only 33% in individuals who accumulated 
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over 1000 k cal/wk.  T his negative association between albuminuria and physical activity was 
independent of blood pressure (systolic and diastolic) and glucose control [238].  The Finnish 
Diabetic Nephropathy (FinnDiane) study which examined the association between leisure time 
physical activity and albuminuria similarly found that compare to individuals who were active, 
inactive individuals had nearly twice the odds of having albuminuria [239].   
The association between physical activity and albuminuria is also documented in 
“healthy” individuals without diabetes.  Robinson et al. examined the association between self-
reported physical activity and albuminuria in women without diabetes using data from the 
Nurse’s Health Study I (NHS I) and the Nurse’s Health Study II (NHS II).  Even at low levels of 
albuminuria (<5 mg/d), individuals with the highest level of physical activity had lower levels of 
albuminuria compared to individuals who self-reported no physical activity [240].    
Few studies have examined the effects of physical activity on albuminuria prospectively.  
Studies in animal models suggest that engaging in moderate intensity physical activity can 
reduce albuminuria [241].  In human studies however, the results a little more mixed.  The DPP 
compared the prevalence of albuminuria in three groups (control, metformin, intense lifestyle-
diet, physical activity, and weight loss) at baseline and at the study’s end.  P revalence of 
albuminuria remained unchanged in both the metformin and intense lifestyle intervention groups.  
Individuals in the control group however, were more likely to have increased albuminuria 
compared to the two intervention arms which bordered on significance (p=0.07) [242].  Another 
prospective study to examine the association between albuminuria, GFR and physical activity 
was the Australian Diabetes Study (AusDiab).  Individuals who self reported at least 150 minutes 
of leisure time physical activity were deemed sufficiently active.  Compared to the sufficiently 
active group, individuals who were inactive had a 1.3 odds of having albuminuria at baseline.  
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Baseline physical activity was not however, associated with incident albuminuria during the five 
year study follow-up [59].  A study by Lazarevic et al. examined the effects of six months of 
moderate physical activity on the prevalence of albuminuria in thirty males with diabetes.  The 
intervention consisted of supervised brisk walking on three to five days per week.  The 
intervention successful reduced the prevalence of albuminuria from 20% to 3.3% [243].  The 
study was limited however by the small sample and lack of control group.    
4.1.6 Physical Activity and Renal Function 
The association between physical activity and eGFR has also been assessed in a few 
epidemiological studies.  Data from NHANES was analyzed by Stengel et al. which examined 
the cross-sectional relationship between subjectively assessed physical activity and the odds 
having CKD.  Individuals were classified as being inactive, moderately active, and very active.  
The results from the study indicated a graded relationship between level of physical activity and 
odds of having CKD.  Compared to the very active group, individuals who were moderately 
active or inactive had a 1.2 and 2.2 odds of having CKD [39].  Another analysis of NHANES 
data by Finkelstein et al. examined the association between physical activity and eGFR 
(estimated using the Cockcroft Gault equation) in individuals with and without metabolic 
syndrome [38].  Physical activity was assessed with a PAQ and was analyzed with three separate 
activity variables: 1) total number of activities performed 2) the number of different types of 
activities 3) total METs.   In individuals without metabolic syndrome, the number of activities 
performed and total METs were positively associated with eGFR.  In individuals with metabolic 
syndrome, only the number of activities performed was positively associated with eGFR.     
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Other population based studies have also shown a relationship between physical activity 
and CKD.  T he second Health Survey of Nord-Trondelag County (HUNT II) study is a 
population based study of adults (>20 years of age) in Norway [40].  CKD was defined by 
having an eGFR <45 mL/min/1.73 m2 (estimated using the MDRD study equation).  Participants 
self-reported the amount of time spent in light or intensity activities during leisure.  Individuals 
who self-reported no leisure physical activity had more the twice the odds of having CKD 
compared to individuals who self-reported at least some activity.   
4.1.7 Conclusions 
There is a p aucity of research which examines the association between physical activity and 
CKD or renal function in humans.  W hile some of the existing literature does support a 
relationship between physical activity and renal function, there are still some unanswered 
questions.  The fact that physical activity can occur along a range of intensity levels raises an 
important question; what levels of intensity of physical activity are related to health outcomes 
such as renal function?  W hile our national recommendations for physical activity advocate 
moderate to vigorous intensity activities, do activities of lower intensity benefit renal health?  
These are questions that current technology allows us to address with the use of an objective 
measure of physical activity, namely accelerometers.  Addressing these questions in future 
examinations will help guide our future intervention efforts in the CKD populations.   
The literature also does not adequately address the relationship between physical activity 
and renal health in minority populations.  Few studies have examined the association between 
physical activity and CKD in minority groups such as American Indians.  Considering the fact 
that American Indians are twice as likely to development CKD as whites, it is  important to 
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explore the potential benefits of modifiable lifestyle factors such as physical activity in this 
population. Existing data sets from the Strong Heart Study may allow us to investigate this area 
further and begin to determine what the potential renal health benefits of physical activity are in 
diverse populations. 
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5.0  CHAPTER 5 
5.1 STUDY OBJECTIVES 
The aim of this dissertation is to examine the relationship between subjectively and objectively 
assessed physical activity with CKD/renal function in both a nationally representative sample of 
the US and a high risk minority population.  Specific methodology for each manuscript will be 
described in further detail later.  In brief, manuscript 1 will describe physical activity objectively 
by race/ethnicity and gender in a nationally representative sample. This will provide insight into 
how active minority populations are in the US and describe how much light, moderate to 
vigorous and total activity is performed in these groups.  This will lead to examination of the 
association between various intensities of physical activity and renal function in the same 
nationally representative sample as the focus of manuscript #2.  We will then determine the 
longitudinal effects of physical activity on this condition in a minority population which is at 
high risk (manuscript #3).   
The Strong Heart Study will be used to determine the association between physical 
activity and CKD/renal function in Native American communities from three geographical 
locations in the US.  Specifically, using data from the Strong Heart Study, we will assess the 
association between baseline levels of self-reported physical activity and incident CKD during 
subsequent clinic visits (1989-1991 and 1993-1995).  Few studies have examined the association 
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between physical activity and CKD/renal function prospectively.  Even fewer have examined 
this association in minority populations such as from Native Americans where the risk of CKD 
development is high. 
5.2 METHODS 
To examine the objectives which were previously described for this dissertation, two data sets 
will be used, the National Health and Nutrition Examination Survey (NHANES) and the Strong 
Heart Study (SHS).  Analysis for manuscripts 1 and 2 will both utilize the NHANES data sets 
from different cycles (manuscript 1:2003-2004, manuscript 2: 2003-2006).  NHANES is cross-
sectional study on a nationally representative sample of non-institutionalized citizens in the US.  
Manuscript 3 will be analyzed using the SHS data set.  The SHS is a longitudinal study of 13 
American Indians tribes from three locations (Phoenix, Oklahoma, North and South Dakota) 
which was designed to examine cardiovascular morbidity, mortality and CVD risk factors.  
Specific information about each study population, data collection methods will be described in 
further detail below. 
5.3 BRIEF OVERVIEW OF NHANES 
In order to describe physical activity levels in nationally representative population by 
race/ethnicity and gender (Manuscript 1) and then examine the relationship between these 
activity levels and renal function (Manuscript 2), the NHANES data set will be used.  NHANES 
 52 
is a cross-sectional observational study conducted by the National Center for Health Statistics of 
the Centers for Disease Control which began in the early 1960s and was conducted as a series of 
surveys focusing on different population groups and health topics.  In 1999, the survey became a 
continuous program that had a changing focus on a variety of health outcomes.  The continuous 
NHANES survey over-samples adolescents (12-19 years of age), persons greater than or equal to 
60 years of age, African Americans, Mexican Americans, and individuals with low income so 
that nationally representative estimates of the civilian non-institutionalized population can be 
generated [244].  Previous NHANES cycles also over-sampled from specific subgroups 
depending on the public health trends at the time.   
The NHANES continuous survey utilizes a complex random survey design which occurs 
in four stages (Figure 2).  D uring the first stage, primary sampling units (PSUs) are selected 
which are, in most cases, counties.  T he second stage consists of dividing these PSUs into 
segments (city blocks).  From these segments, households are then randomly selected.  In the 
final stage, individuals are randomly selected from each household for inclusion in the survey.  
Each selected individual is assigned a sample weight which is an estimate of how many people 
they represent in the general population.  That sample weight reflects the unequal probability of 
being selected as well as adjustments for non-response and other factors.  It’s important to take 
into consideration the complex survey design as well as the sampling weights into all analysis of 
NHANES data.  Failure to take the complex design factors into consideration may lead to bias 
estimates and overstating significance [245].          
Data for NHANES is collected by trained clinicians in Mobile Examination Centers 
which travel to each location across the country. Personal interviews are conducted, in the 
participant’s home, in which demographic, socioeconomic, dietary, and health-related questions 
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on behaviors such as physical activity are collected.  In addition to detailed survey data, trained 
medical staff collects information on medical, dental, and physiological measurements, as well 
as laboratory tests (e.g. creatinine, fasting lipids).  
5.3.1 Measures 
5.3.1.1 Demographics  
Demographic information such as age, race/ethnicity, health status, and education was assessed 
by questionnaire during the in home interview.  Participants were categorized as non-Hispanic 
white, non-Hispanic black, and Hispanic (including Mexican American and other Hispanic) 
based on self-report.  Age in years was calculated from self-report.  Participants over the age of 
85 were assigned the age of 85 to protect confidentiality.  General health status was self-reported 
as excellent, very good, good, fair, or poor.  Education was determined by questionnaire: “What 
is the highest grade or level of school you have completed or the highest degree you have 
received?”  Participants were categorized as: “Some college or beyond” or “High school or less”. 
5.3.1.2 Physical Activity   
Since the annual NHANES survey started in 1999, a self reported (questionnaire) measure of 
physical activity has been included in each cycle.  The physical activity questionnaire used in 
NHANES assesses activities of moderate and vigorous intensity performed during the last 30 
days from three domains: household, transportation, and leisure.  A ctivities performed for 
transportation was assessed by asking participants if they walked or biked to school, work, or to 
do errands.  To assess household activities, participants were asked if they performed any 
activities of moderate intensity or greater around the home or yard for ten minutes.  To assess 
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activities performed during leisure, more detailed information about 47 s pecific activities of 
moderate or vigorous intensity was queried (e.g. walking, running, swimming, yoga, tennis, etc).  
Participants were also asked if they engaged in any muscle strengthening activities such as push-
ups or calisthenics.  The NHANES physical activity questionnaire also asks participants to report 
the amount of time spent during sedentary activities (TV watching and computer use). 
In the 2003-2004 study cycle, NHANES began to assess physical activity objectively 
with an accelerometer.  Physical activity was assessed with the Actigraph AM-7164 
accelerometer (formerly the CSA/MTI AM-7164, manufactured by ActiGraph of Ft. Walton 
Beach, FL), which is a pager size device powered by a small lithium battery.  The accelerometers 
were attached to an elasticized belt and worn on the right hip.  The accelerometer measures the 
duration and intensity of physical activity by capturing the magnitude of acceleration (intensity) 
and summing up the magnitudes (intensity counts) within a specified time interval (epoch).  We 
used a one-minute epoch.    
Participants were asked to wear the device for seven days while they were awake, and to 
take it o ff for swimming or bathing.  Monitors were returned by express mail to NHANES, 
where data were downloaded from the device, and the device was checked to determine whether 
it was still within the manufacturer’s calibration specifications using an Actigraph calibrator.  
NHANES used standardized data quality procedures to maximize the accuracy of the 
accelerometry data, which are described in more detail elsewhere [246].   In brief, participants 
with at least four days in which the accelerometer was worn for at least 600 minutes are included 
in analysis.  Any block of time greater than or equal to 60 minutes where the activity count was 
equal to zero was considered time when the monitor was not worn.  B ased on a  previous 
calibration study by Freedson and colleagues, a minute of accelerometer data was coded as 
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sedentary if it contained less than 260 a ctivity counts.  A  minute was coded as light physical 
activity if it recorded an accelerometer count between 260-1951.  A  minute was coded as 
moderate-vigorous intensity if activity counts were greater than or equal to 1952 [174].  Counts 
derived during minutes of light and moderate-vigorous activity respectively, were individually 
summed and divided by the number of days worn to calculate daily averages for those specific 
intensities.  Total physical activity was the sum of the counts derived during minutes of light and 
moderate-vigorous activity.       
5.3.1.3 Laboratory Data 
Serum creatinine was assessed by the Jaffe rate reaction method.  Serum creatinine levels were 
used to estimate glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease 
(MDRD) study formula:  eGFR = 1.86.3 X serum creatinine (mg/dL) -1.154 X age -0.203 (X 0.742 
for women) (X 1.21 f or Non-Hispanic Black).   Urinary albumin was assessed using a solid-
phase fluorescent immunoassay described by Chavers et al [247]. Urinary creatinine was 
assessed using the Jaffe rate reaction method with a CX3 analyzer.  The albumin to creatinine 
(A/C) ratio was defined with the following equation: urinary albumin/urinary creatinine.  
Microalbuminuria was defined as having an A/C ratio > 30 mg/g.  Renal function was classified 
into five stages based on the National Kidney Foundation KDOQI guidelines for defining 
CKD[248]:  
 
1) Normal = e GFR between 90 - 130 mL/min/1.73 m2 with no evidence of renal damage 
(A/C ratio <30 mg/g);  
2) Stage 1 = eGFR between 90 - 130 mL/min/1.73 m2 plus evidence of renal damage (A/C 
ratio >30 mg/g);  
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3) Stage 2 = eGFR between 60 - 89 mL/min/1.73 m2  plus evidence of renal damage   
4) Stage 3 was divided into early (3a) and late (3b) sub-categories [81] 
a. Stage 3a = eGFR between 46 - 59 mL/min/1.73 m2 
b. Stage 3b = eGFR between 30 - 45 mL/min/1.73 m2.   
Individuals with eGFR <30 mL/min/1.73 m2 were dropped from the analysis since the 
disease had progressed into late stages and the objective of the study was to examine the 
association between physical activity and renal function at early stages of the disease.  
Remaining individuals were then dichotomized into two groups based on r enal function: 1) 
normal and 2) mild to moderate renal function (CKD stages 1-3b).    
To assess serum lipid levels as part of NHANES, blood samples were drawn from 
individuals over the age of six by trained clinicians in the MEC’s.  Fasting was not required for 
all blood draws, however, approximately 1/3 of the participants (those who attended the morning 
session) were asked to provide a fasting sample.  Both total cholesterol and HDL cholesterol was 
assessed on all participants regardless of fasting status.  Total cholesterol was assessed 
enzymatically and HDL cholesterol was measured using the Roche/Boehringer-Mannheim direct 
HDL method.  T riglycerides were assessed using a timed-end point method only from 
participants who provided a fasting blood sample.  LDL cholesterol was estimated with the 
following equation: total cholesterol – HDL cholesterol – triglycerides/5, where triglycerides/5 is 
an estimate of VLDL cholesterol [246].     
Fasting glucose was assessed only on those participants who provided a fasting sample.  
Glucose concentrations was assessed by measuring the concentrations of nicotinanide aden ine d 
inucleotide (NA DH) spectrophotometrically at 340 nm.  N A DH concentrations are directly 
proportional to glucose concentrations [246].  Fasting glucose levels were used to assess diabetes 
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status.  Individuals with a f asting glucose level above 125 mg/dL , self reported as having 
diabetes, or self-reported use of insulin were classified as having diabetes [249].   
Other laboratory measures included serum cotinine and C-reactive protein (CRP).  Serum 
cotinine was used to assess currently smoking status.   Current smoking status was determined as 
having a serum cotinine greater than 3 ng/mL.  CRP was measured to assess systemic 
inflammation using latex-enhanced nephelometry during the examination visit [246]. 
5.3.1.4 Anthropometrics 
Weight was measured in pounds on a  Toledo digital scale.  Weight was then converted into 
kilograms using standard procedures.  Height was measured in centimeters with a vertical ruler.  
The participants were asked to stand completely straight with their feet flat on the ground.  The 
back of the head was against the vertical board aligned in the Frankfort horizontal plane.   Body 
Mass Index (BMI) was calculated by dividing weight in kilograms by height in meters squared 
(kg/m2).  Waist circumference was also used as a measure adiposity.   Waist circumference in 
centimeters was measured across the midaxillary line  of the body with the participant asked to 
breathe quietly [250]. Measured where across the midaxillary line of the body (the midaxillary 
line is an imaginary line through the axilla parallel to the long axis of the body and midway 
between its ventral and dorsal surfaces) 
5.3.1.5 Blood Pressure 
Systolic and diastolic blood pressures were measured by trained clinicians using standard 
procedures on the participant’s right arm with a mercury sphygmomanometer.  A more detailed 
description of the procedures for measuring blood pressure are available elsewhere [250].  In 
brief each participant was instructed to sit quietly for five minutes before MEC clinicians 
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attempted three blood pressures measures.  Pulse pressure was determined by taking the 
difference between systolic and diastolic pressure.   Mean arterial pressure (MAP) was calculated 
with the following formula: MAP = diastolic + pulse pressure/3.    
5.3.2 Statistical Analysis 
The primary objective and hypothesis for manuscript 1 and manuscript 2 are briefly described 
below.  More detailed analysis plans are described within the context of each paper. 
5.3.2.1 Paper #1: Objectively measured physical activity of U.S. adults by sex, age, and 
racial/ethnic groups: a cross-sectional study 
The purpose of paper #1 was to examine differences in physical activity by sex, age and 
racial/ethnic groups in a national sample of adults.  Specific detailed information about the 
analysis plan and results can be found in the context of the manuscript, which was published in 
the International Journal of Behavior Nutrition and Physical Activity in 2009 and is attached in 
the appendix.  The abstract for paper 1 is provided below:  
Background: Accelerometers were incorporated in the 2003-2004 National Health and 
Nutritional Examination Survey (NHANES) study cycle for objective assessment of physical 
activity.  This is the first time that objective physical activity data are available on a nationally 
representative sample of U.S. residents.  The use of accelerometers allows researchers to 
measure total physical activity, including light intensity and unstructured activities, which may 
be a better predictor health outcomes than structured activity alone.  The aim of this study was to 
examine objectively determined physical activity levels by sex, age and racial/ethnic groups in a 
national sample of U.S. adults. 
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Methods: Data were obtained from the 2003-2004 NHANES, a cross-sectional study of a 
complex, multistage probability sample of the U.S. population.  Physical activity was assessed 
with the Actigraph AM-7164 accelerometer for seven days following an examination.  2, 688 
U.S. adults with valid accelerometer data (i.e. at least four days with at least 10 hours of wear-
time) were included in the analysis.  Mean daily total physical activity counts, as well as counts 
accumulated in minutes of light, and moderate-vigorous intensity physical activity are presented 
by sex across age and racial/ethnic groups.  G eneralized linear modeling using the log link 
function was performed to compare physical activity in sex and racial/ethnic groups adjusting for 
age. 
Results: Physical activity decreases with age for both men and women across all 
racial/ethnic groups with men being more active than women, with the exception of Hispanic 
women.  Hispanic women are more active at middle age (40-59 years) compared to younger or 
older age and not significantly less active than men in middle or older age (i.e. age 40-59 or age 
60 and older).  Hispanic men accumulate more total and light intensity physical activity counts 
than their white and black counterparts for all age groups.  
Conclusion: Physical activity levels measured objectively by accelerometer 
demonstrated that Hispanic men are, in general, more active than their white and black 
counterparts.  This appears to be in contrast to self-reported physical activity previously reported 
in the literature and identifies the need to use objective measures in situations where the 
contribution of light intensity and/or unstructured physical activity cannot be assumed 
homogenous across the populations of interest.  
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5.3.2.2 Paper #2: The association between physical activity and renal function: NHANES 
The purpose of this study is to determine the association between time spent at all levels of 
physical activity intensity (light, moderate to vigorous, total, and sedentary) and renal function in 
a nationally representative population.  Specific detailed information about the analysis plan and 
results can be found in the context of the manuscript, which was submitted to Medicine and 
Science and Sport and Exercise in August 2010, and is also attached in the appendix.  The 
abstract for manuscript 2 is provided below: 
Background: Chronic kidney disease (CKD) is a condition characterized by the 
deterioration of renal function which can lead to end stage renal disease (ESRD).   Previous 
studies have shown that physical activity may have renal benefits.  One question that remains is 
what intensity of physical activity is related to these beneficial effects.  The purpose of this study 
is to determine the association between time spent at all levels of physical activity (light, 
moderate to vigorous, total, and sedentary) and renal function in a nationally representative 
population. 
Methods: Data were obtained from the 2003-2004 and 2005-2006 NHANES, a cross-
sectional study of a complex, multistage probability sample of the U.S. population.  P hysical 
activity was assessed with the Actigraph AM-7164 accelerometer for seven days following an 
examination.  A minute of accelerometer data was coded as either sedentary (counts <100), light 
(counts between 100-1952), or moderate to vigorous (counts >1952).  Glomerular filtration rate 
was estimated using the Modification of Diet in Renal Disease (MDRD) study formula.  T o 
assess linear associations between levels of physical activity and sedentary activity with log 
transformed eGFR, linear regression was used.   
 61 
Results: In general, physical activity (light and total) was related to log eGFR in females 
and males.  For females, the association between light and total physical activity with log eGFR 
was consistent regardless of diabetes status.  For males, the association between light and total 
physical activity and log eGFR was only significant in males without diabetes. 
Conclusions: To the author’s knowledge, this was the first study to examine the 
association between physical activity, measured objectively with an accelerometer, and eGFR.  
The results of our analysis indicate that total and light physical activities are positively associated 
with log eGFR. 
5.3.2.3 Paper #3: The Association between Physical Activity and Chronic Kidney Disease in 
Native Americans:  Strong Heart Study 
The purpose of this paper is to determine the association between subjectively assessed physical 
activity and the development of CKD in American Indians.  Using data from the Strong Heart 
Study, we will assess the association between baseline levels of subjectively assessed physical 
activity and the 10 year incidences of CKD.  W e will also examine the association between 
baseline (subjectively assessed) physical activity with change in renal function over the same 
time frame. The background and proposed analysis for this effort is presented in more detail in 
Chapter 6. 
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6.0  CHAPTER 6 
6.1 BRIEF OVERVIEW OF THE STRONG HEART STUDY 
The SHS was the largest epidemiologic study of cardiovascular disease and its risk factors 
among American Indian men and women.   T he SHS was designed to estimate cardiovascular 
disease mortality and morbidity and the prevalence of known and suspected cardiovascular 
disease risk factors in American Indians and to assess the significance of these risk factors in a 
longitudinal analysis.  The study included thirteen American Indian tribes and communities in 
three geographic areas: 1) an area near Phoenix, Arizona (Gila River and Salt River 
Pima/Maricopa, and Akchin Pima/Papago), 2) the southwestern area of Oklahoma (Apache, 
Caddo, Comanche, Delaware, Fort Sill Apache, Kiowa and Wichita), and 3) western and central 
North and South Dakota (Oglala Sioux, Cheyenne River Sioux, and Spirit Lake Communities).  
The SHS assessed physical activity subjectively with the Modifiable Activity Questionnaire at 
baseline and collected measures of renal function during all three examination visits.    
In its initial stages, the SHS included three components.  The first was a survey to 
determine cardiovascular disease mortality rates from 1984 to 1994.  Individuals were eligible 
for the study if they lived in one of the tribal areas for at least six months and were between the 
ages of 45-74 during the two year examination cycle.  Participants were recruited through a local 
tribal population list and community advertisements.  SHS was able to collect clinical 
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examinations of 4,549 tribal members between the ages of 45-74 (62% of the total population in 
age group).   
A follow-up of the original cohort was performed between 1993 and 1995 to gather more 
information about cardiovascular disease risk factors in American Indians.  T he SHS re-
examined 89% of the surviving members of the original cohort.  A  second follow-up was 
performed between 1998 and 1999 where 88% of the surviving cohort was re-examined.  The 
purpose of this manuscript is to examine the association between baseline physical activity and 
the development of CKD during these two follow-up visits using these clinical examination data.  
More detailed information about the measures used to assess physical activity and CKD are 
explained below.    
6.1.1 Measures 
Clinical examinations were collected for all participants at local Indian Health Services (HIS) 
hospitals and clinics by trained staff.  During the examinations, personal interviews and physical 
examinations were performed at which time demographic, medical history, self reported physical 
activity, diet, anthropometric, and laboratory information was collected.   
6.1.1.1 Physical Activity 
Physical activity was assessed with the Modifiable Activity Questionnaire (MAQ) [251]. The 
MAQ is an interview administered questionnaire which asks participants to recall moderate and 
high intensity leisure and occupational activities performed during the past year.  T he leisure 
activity portion of the questionnaire is composed of activities which are most commonly 
performed by the target population and was developed during pilot testing of the questionnaire.  
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As the interviewer reads from the list of activities, the participant indicates which of those 
activities they have performed.  Participants are then asked to estimate the average frequency and 
duration they performed those activities.   
The MAQ also assess inactivity by asking participants about the average number of hours 
per day they usually spend watching television.  Also, included was a question that attempted to 
estimate the extent to which their activity was limited by asking whether the individuals has 
spent one or more weeks confined to a bed or chair because of injury, illness, or surgery.   
To assess occupational activities, participants were asked about each job held over the 
past year for at least a month.  Each job “entry” is assigned a job code which best categorizes the 
job.  Occupations such as homemaker, retired, unemployed, or disable, are listed if no other job 
is identified.  Participants are then asked about their usual transportation to that job as well as 
typical job schedule (days/week and hours/day).  If the participant walks or bikes for 
transportation, the average duration is recorded.  Based on the average hours per day the 
individual spent on the job, the participant is asked to estimate the number of hours spent sitting 
out of the total hours per day at that job.  Finally, they are asked about the types of activities 
performed on the job when they are not sitting.  The interviewer then assigns a letter code which 








Table 6.1 Modifiable Activity Questionnaire Categories for Occupational Activities 
Category A 
(Includes all sitting activities) 
Category B 
(includes most indoor activities) 
Category C 
(heavy industrial work, outdoor 
construction, farming) 
• Sitting 
• Standing still w/o heavy      
lifting 
• Light cleaning 
• Driving a bus, taxi, tractor 
• Jewelry making/weaving 
• General office work 
• Occasional/short distance 
walking 
 
• Carrying light loads 
• Continuous walking 
• Heavy cleaning 




• Electrical work 
• Sheep herding 
• Carrying moderate to 
heavy loads 
• Heavy construction 
• Farming, hoeing, digging, 
mowing, raking 
• Digging ditches, shoveling 
• Chopping (ax), sawing 
wood 
• Tree/pole climbing 
• Water/coal/wood hauling 
 
Leisure activities are calculated by summing the hours for all activities listed.  Activity 
can also be expressed by their weighted metabolic cost (MET) by multiplying the hours spent for 
each specific activity by that activity’s estimated MET value.  Hours of occupation activities are 
calculated with the following equation if category B is selected: 
 (12 months/year) X (4 week/month) X (days/week) X (h/day of moderate activity) / 52 
weeks/year 
[where h/day = (average hours/ day at the job-sitting hours) + (min/day walking or bicycling to 
work / 60) ] 
If category C is selected, and the number of minutes walked or biked to/from work equals 
zero, the following equation is used: 
(12 month/year) X (4 week/month) X (days/week) X (hours/day – hours sitting) / 52 weeks/year 
If category A or category C is selected, and the number of minutes walked or biked 
to/from work does not equals zero, the following equation is used 
[(12 month/year) X (4 week/month) X (days/week) X (min/day walked or biked to/from work / 
60)] / 52 weeks/year 
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To express by their weighted metabolic cost, the hours per week are multiplied by 4 and 
7 for categories B and C respectively.  Note that no activity credit is given for category A.   
The weekly total physical activity is assessed by averaging the sum of past year leisure and 
occupational activities.   
The MAQ was only administered at baseline.  To assess activity status at exam 2, 
participants were asked if their activity levels changed from exam 1.  I f they asked yes, they 
were asked if their activity levels had increased or decreased.   
6.1.1.2 Anthropometrics 
Height was measured in centimeters with a v ertical rule.  T he participant was asked to stand 
completely straight with their back against the wall.  Each measurement was rounded to the 
nearest centimeter.  W eight was measured with the participant standing in the middle of a 
balance scale.  Each measurement was rounded to the nearest kilogram.  Body mass index (BMI) 
was calculated as weight in kg divided by height in meters squared.  Waist circumference in 
centimeters was measured at the level of the umbilicus (navel) with the patient supine and the 
participant is instructed to "breathe quietly".     
6.1.1.3 Fasting Blood Samples  
Fasting blood samples were used to measure lipids, glucose, insulin, creatinine, fibrinogen, and 
HbA1c on all individuals including those on r enal dialysis or renal replacement therapy when 
possible.  Lipid measures included HDL, LDL, VLDL triglycerides, total cholesterol, and ApoA-
I and ApoB lipoproteins.  A ll lipids were analyzed using the Hitochi Hitach 705 clinical 
chemistry analyzer.  S erum creatinine, at Exams 1 and II were assessed using the automated 
alkaline picrate methodology on a rapid flow analyzer.  Serum creatinine was assessed using a 
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different assay at Exam III so all analysis for of creatinine data was only performed using Exam I 
and II data.     
Fasting glucose was assessed on a H itachi analyzer using a glucose oxidase technique.  
Fasting glucose concentrations will be used to define normal fasting glucose, impaired fasting 
glucose, and diabetes according to criteria developed by the ADA.  Insulin was assessed with an 
overnight radioimmunoassay using the Morgan and Lazarow method [252].  If individuals are 
being treated with insulin, their data will be analyzed separately.  Insulin resistance will be 
estimated using the homeostasis model which is calculated with the following formula: HOMA-
IR = fasting serum insulin (uU/ml) X fasting plasma glucose (mmol/l)/22.5[253].  
6.1.1.4 Urinary Analysis 
Urinary analysis was performed at the NIDDK lab for exams 1 and 2.  Exam 3 urinary analysis 
was performed at the PML using the same methodology.  After fasting blood samples were 
collected, participants were asked to provide a urine specimen.  Urinary albumin was assessed 
using an automated nephelometric immunochemical procedure with a Behring Nephelometer.  
Urinary creatinine was assessed using automated alkaline picrate methodology on a rapid flow 
analyzer.   
6.1.1.5 Physical Examination 
Blood pressure was measured after participants were rested for 5 minutes, using 3 measurements 
with a B aum mercury sphygmomanometer.  H ypertension will be defined as having a blood 
pressure >=140 or >=90mmHg, self reported physician diagnosed hypertension, or taking blood 
pressure medications.   
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6.1.1.6 Personal Interview 
A personal interview was conducted by study clinicians where demographic information, 
medical history, physical activity and dietary information were collected.  Current smoking 
status will be determined through self report.  Participants will be asked if they currently or ever 
smoked cigarettes or other tobacco products such as pipes or cigars.  Alcohol intake will be 
collected through self report as the number of alcoholic beverages consumed per week.  During 
the examination, participants will be asked about their current and medical history including 
current medications taken (blood pressure, lipid lowering) and history of cardiovascular disease 
(heart failure, stroke, etc.).   
6.1.2 Statistical Analysis 
The proposed analytical procedures for paper # 3, The Association between Physical Activity and 
Chronic Kidney Disease in Native Americans:  Strong Heart Study, are briefly described below.   
The primary aim of paper #3 is to determine the association between baseline physical 
activity and change in kidney function during follow-up visits.  We also plan to look at baseline 
physical activity and the incidence of CKD and/or albuminuria during follow-up.  To test these 
aims the following statistical procedures will be performed: 
Physical activity will be coded into three groups.  Among those individuals who reported 
any leisure or occupational activity, their activity levels will be divided into two groups (above 
and below the median).  Individuals who reported no leisure or occupational activity will be the 
reference group.      
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AIM 1: To determine the relationship between physical activity at baseline 
and change in eGFR during follow-up 
 
HO1: Individuals who are less physically active at baseline will have a 
greater decrease in renal function compared to individuals who are more active at 
baseline.   
 
To test this hypothesis, generalized linear modeling using a repeated measures design 
will be used.  Individuals with and without CKD at baseline will be included in the analysis.  
Follow-up will include Exam I and II because they used the same assay to assess serum 
creatinine. Exam III will be omitted from this analysis because a d ifferent assay was used to 
assess serum creatinine.  We also excluded individuals who were on dialysis during exams 1 or 
2.  Estimated GFR will be the dependent variable and modeled as a function of baseline physical 
activity as the primary predictor.  Physical activity will be coded into three groups.  Among those 
individuals who reported any leisure, their activity levels will be divided into a high and low 
activity group (above and below the median), with the high activity group being the reference.  
Individuals who reported did not report any leisure activity will be the “no LTPA” group.   A 
variety of models will be fit that adjust for covariates (age, gender, baseline eGFR, baseline 
ACR, clinic site, hypertension status, smoking status, lipid levels, history of heart failure, and 
BMI.)    
 
AIM 2a: To determine the relationship between baseline physical activity 
and the incidence of albuminuria. 
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HO2a: Individuals who are less physical active at baseline will have a higher 
incidence of albuminuria during follow-up.   
 
To test this hypothesis logistic regression will be performed.  In this analysis individuals 
free from albuminuria at baseline will be identified and their subsequent disease status will be 
determined at the Examination II and III clinic visits. Anyone who develops albuminuria will be 
considered a case.  Physical activity will be coded into three groups.  Among those individuals 
who reported any leisure, their activity levels will be divided into a high and low activity group 
(above and below the median), with the high activity group being the reference.  Individuals who 
reported did not report any leisure activity will be the “no LTPA” group.   Multivariate analyses 
using logistic regression modeling will be used to determine if there is an association between 
physical activity and the odds of developing albuminuria during study follow-up. A variety of 
models will be fit that adjust for covariates (age, gender, baseline eGFR, clinic site, hypertension 
status, smoking status, lipid levels, baseline ACR, and BMI.)       
 
AIM 2b: To determine the relationship between baseline physical activity 
and the incidence of CKD. 
 
HO2b: Individuals who are less physical active at baseline will have a higher 
incidence of CKD during follow-up.   
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To test this hypothesis, logistic regression will be performed.  In this analysis individuals 
free from CKD at baseline will be identified and eGFR will also be determined at the 
Examination II clinic visit. Exam III will be omitted from this analysis because a different assay 
was used to assess serum creatinine.  Our outcome measure will be the presence or absence of 
CKD (eGFR <60 mL/min/1.73 m2). Anyone who develops CKD during the follow-up time 
period will be considered a case.  Physical activity will be coded three groups.  Among those 
individuals who reported any leisure, their activity levels will be divided into a high and low 
activity group (above and below the median), with the high activity group being the reference.  
Individuals who reported did not report any leisure activity will be the “no LTPA” group.   
Multivariate analyses using logistic regression modeling will be used to determine if there is an 
association between physical activity and the odds of developing CKD during study follow-up. A 
variety of models will be fit that adjust for covariates (age, gender, baseline eGFR, clinic site, 
hypertension status, smoking status, lipid levels, history of heart failure, albuminuria, and BMI.)   
6.1.3 Statistical Power Calculations 
To calculate statistical power for these analyses, G Power 3.1.2 software was used [255].  The 
primary aim of this dissertation is to determine the association between physical activity (none, 
low, high) at baseline and change in eGFR during follow-up.   There were 4549 individuals in 
SHS at baseline out of which, 2,993 individuals had available data on baseline physical activity 
and eGFR at exams 1 and 2.  Assuming that the correlation between eGFR at exams 1 and 2 will 
be 0.30, we will have 95% power to detect a small effect size of 0.05 between the three activity 
groups.  If we assume that the correlation between eGFR at the two exam visits will be 0.50, we 
would also have 95 % power to detect that same effect size (See table 6.2).     
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Table 6.2 Statistical power analysis for repeated measures ANOVA 
Effect Sizes Sample Size Correlation*  Statistical Power Correlation8  Statistical Power 
0.05 2993 0.30 95 0.50 95 
0.10 2993 0.30 95 0.50 95 
0.25 2993 0.30 95.2 0.50 95.1 
0.35 2993 0.30 95.5 0.50 95.3 
*Correlation between repeated measures (eGFR) at examination visits 1 and 2 
 
The second aim of the dissertation was to determine the association between baseline 
physical activity and the incidence of albuminuria.  There were 2405 individuals with available 
data on baseline physical activity albuminuria at all three exams, of which 1876 were free from 
albuminuria at baseline.  At baseline, 30% of the individuals who self-reported no leisure 
physical activity had albuminuria compared to 19% of the individuals who self-reported high 
physical activity levels.  Assuming a similar percentage of individuals will develop albuminuria 
during follow-up in these respective activity groups, we would 96.4% power to detect a 
difference in the incidence of albuminuria in these groups.  If the proportion of individuals who 
develop albuminuria in the self-reported no activity group is 28% compared to 19% in 
individuals in the high activity group, we would have 88.6% power to detect a difference in the 
incidence of albuminuria in these groups (See table 6.3). 
Table 6.3 Statistical power analysis between proportions of two independent groups 
Sample Size Group1† Sample Size Group 2# Proportion Difference 
(proportion 1– proportion 2)* 
Statistical Power 
710 1614 11 96.4 
710 1614 9 99.6 
710 1614 7 72.3 
*The difference between the proportion of individuals who develop albuminuria in no activity compared to the high 
activity group 
†the number of participants who reported no leisure physical activity 
#the number of participants who reported high levels of leisure physical activity 
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6.1.4 Baseline Characteristics 
At baseline, the SHS included 4549 individuals, 4060 of which had available data on GFR, 
physical activity, and relevant covariates (See Figure 3).  Individuals who were not included in 
this analysis were similar in age, BMI, HDL and LDL cholesterol, and percentage who reported 
they currently smoked compared to the individuals who were included.  Individuals who were 
excluded were however, more likely to have hypertension, diabetes, and albuminuria (p<0.05).  
A slightly higher percentage of the individuals who were not included in this analysis also had 




Figure 6-1 Participant flow chart 
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The individuals included in this analysis were between the ages of 45 and 74(mean age 
56).  A pproximately 60% of the participants were women.  Table 6.4 describes the baseline 
characteristics of the populations stratified by gender.  C KD and albuminuria were highly 
prevalent at baseline with women carrying a higher burden of these conditions compared to men 
(p<0.01).  Albuminuria was prevalent in approximately 27% of men and 30% of women.  The 
prevalence of CKD was approximately 5% in men and women had more than double  t he 
prevalence (13.34%) of CKD compared to men.  R isk factors for CKD and albuminuria were 
also high in this population.  Approximately 40% of men and 46% of women had diabetes at 
baseline.  Hypertension was prevalent in approximately 40% of men and 38% of women.  Men 
and women in this cohort also had a high prevalence of obesity.  Men and women had an average 
BMI of 30 and 31.6 respectively.  Physical inactivity was also prevalent in this population with 
approximately 16% of men and 19% of women reporting no p articipation in any physical 
activities during leisure. 






Age (+ SD) 55.8 56.6 <0.01 
BMI (+ SD) 30.0 31.6 <0.01 
Smoking status  
% yes 
40.7 29.4 <0.01 
Hypertension 
% yes  
40.2 37.6 0.10 
Diabetes Status 40.5 46.0 <0.01 
HDL (+ SD) 43.3 48.1 <0.01 
LDL (+ SD) 118.7 115.8 0.01 
Total Cholesterol 
(+ SD) 
188.3 191.1 0.02 
Triglycerides (+ SD) 131.2 136.2 <0.01 
CKD % 5.28 13.34 <0.01 
Albuminuria  %  26.71 30.18 0.02 
No LTPA 16.0 19.4 0.01 
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Characteristics of the population at baseline by study center are presented in Tables 6.5 
and 6.6 for men and women respectively.  Of the 3,967 individuals included in the analysis, there 
were approximately an equal number of individuals from each study center (AZ=1312, 
OK=1339, SD=1316).  Individuals from Arizona had higher BMI’s, a higher burden of diabetes 
and albuminuria, and were less physically active than the Dakota and Oklahoma centers.  The 
prevalence of CKD however, was highest in women from Oklahoma compared to women from 
the other centers.  The mean age between the centers were fairly similar though men from 
Arizona were slightly younger than individuals from the other centers (women: AZ=56, 
OK=57.3, SK=56.4 yrs; men: AZ=54.8, OK=56.2, SD=56.3 yrs). 
 
Table 6.5 Descriptive Characteristics at Baseline for Women by Study Center 
 AZ (N=861) OK(N=786) SD (N=771) Total (N=2418) 
Age (+ SD) 56.0 57.3 56.4 <0.01 
BMI (+ SD) 33.3 31.1 30.2 <0.01 
Smoking status  
% yes 
12.8 31.2 46.1 <0.01 
Hypertension 
% yes  
41.9 42.3 28.0 <0.01 
Diabetes Status  
%  
65.7 35.6 34.5 <0.01 
HDL (+ SD) 46.7 49.9 49.0 <0.01 
LDL (+ SD) 105.9 117.7 124.8 <0.01 
Total Cholesterol 
(+ SD) 
179.7 194.6 200.3 <0.01 
Triglycerides (+ SD) 140.7 134.8 132.7 0.02 
CKD %  12.5 15.2 12.4 0.18 
Albuminuria %  48.8 20.3 19.3 <0.01 
GFR  
mL/kg/min 
81.8 76.0 87.1 <0.01 








Table 6.6 Descriptive Characteristics at Baseline for Men by Study Center 
 AZ (N=479) OK(N=583) SD (N=658) Total (N=1642) 
Age (+ SD) 54.8 56.2 56.3 <0.01 
BMI (+ SD) 31.4 30.3 28.5 <0.01 
Smoking status  
% yes 
31.4 36.3 52.8 <0.01 
Hypertension 
% yes  
44.8 47.0 29.3 <0.01 
Diabetes Status  
% 
58.9 37.4 28.6 <0.01 
HDL (+ SD) 44.3 41.7 44.2 <0.01 
LDL (+ SD) 102.9 123.3 127.1 <0.01 
Total Cholesterol 
(+ SD) 
173.3 192.7 196.1 <0.01 
Triglycerides (+ SD) 130.6 138.5 124.5 <0.01 
CKD %  6.3 6.0 3.8 0.13 
Albuminuria %  43.3 21.1 18.8 <0.01 
GFR  
mL/kg/min 
92.7 82.4 85.5 <0.01 
No LTPA 22.5 10.0 16.6 <0.01 
 
Table 6.7 provides descriptive characteristics at baseline of men and women by age group 
(45-54yrs, 55-64yrs, >65yrs).  In general, as individuals aged, the prevalence of diabetes, 
hypertension, CKD, and albuminuria increased and (p<0.01).  Physical individual also increased 
with age.  In addition, smoking status and BMI were lower in older individuals (p<0.01).  In 


























BMI (+ SD) 30.7 29.5 28.4 <0.01 31.9 31.8 30.5 <0.01 
Smoking status  
% yes 
43.1 41.5 32.3 0.01 35.1 26.5 20.2 <0.01 
Hypertension 
% yes  
35.6 41.5 52.5 <0.01 26.8 41.4 58.5 <0.01 
Diabetes status % yes 39.5 41.9 41.8 0.62 39.9 51.5 52.3 <0.01 
HDL (+ SD) 43.4 43.7 42.1 0.31 47.4 48.7 48.9 0.03 
LDL (+ SD) 120.6 117.8 113.6 0.01 115.2 117.6 114.9 0.24 
Total Cholesterol 
(+ SD) 
190.9 186.5 181.5 <0.01 189.6 194.2 191.0 0.04 
Triglycerides (+ SD) 135.1 124.6 128.7 0.06 134.9 139.1 136.0 0.16 
CKD %  2.6 6.3 12.2 <0.01 5.7 15.2 30.6 <0.01 
Albuminuria %  25.3 25.0 33.1 0.03 26.4 31.1 38.6 <0.01 
GFR mL/kg/min 90.4 84.1 78.4 <0.01 83.4 77.3 69.8 <0.01 
No LTPA % 10.6 18.6 28.1 <0.01 14.4 21.7 27.9 <0.01 
 
Presented in Table 6.8 are descriptive characteristics of the population at baseline by 
CKD status for men and women.  As expected, individuals with CKD had a higher prevalence of 
diabetes and hypertension (p<0.01).  In addition, women with CKD had higher triglycerides, 
LDL and total cholesterol compared to women without CKD (p<0.01).  M en with CKD had 
lower levels of HDL cholesterol compared to men without CKD (p=0.01).  O f interest, even 
individuals without CKD at baseline had a high prevalence of risk factors for CKD.  In those 
individuals without CKD, diabetes was prevalent in approximately 40% of men and 44% of 
women.  Hypertension was prevalent in approximately 39% of men and 34% of women without 
CKD at baseline. 
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Table 6.8 Descriptive characteristics of Strong Heart Study participants at baseline stratified by 
CKD and gender 
 Men Women 









Age (+ SD) 55.5 (7.9) 61.4 (8.6) <0.01 55.6 (7.8) 62.4 (7.7) <0.01 
BMI (+ SD) 30.0 (5.9) 29.9 (7.9) 0.92 31.8 30.6 <0.01 
Smoking status  
% yes 
41.5 25.0 <0.01 30.1 24.6 0.05 
Hypertension 
% yes  
38.8 65.4 >0.01 33.7 63.1 <0.01 
Diabetes Status 39.7 56.0 <0.01 44.4 56.5 <0.01 
HDL (+ SD) 43.5 (13.5) 39.5 (15.1) 0.01 47.9 (21.8) 49.3 (14.4) 0.08 
LDL (+ SD) 119.0 (32.7) 113.5 (34.9) 0.15 115.0 (32.3) 120.8 (41.7) <0.01 
Total Cholesterol 
(+ SD) 
188.6 (36.7) 181.4 (38.5) 0.08 189.7 (37.0) 200.3 (48.6) <0.01 
Triglycerides  
(+ SD) 
130.6 (71.5) 142.1 (72.7) 0.07 133.9 (68.5) 151.2 (75.4) <0.01 
Albuminuria  
%  
24.8 61.9 <0.01 26.4 54.6 <0.01 
No LTPA 15.4 26.2 0.01 17.8 29.7 <0.01 
 
Individuals with CKD self-reported higher levels of inactivity compared to individuals 
without CKD (p<0.01).  CKD was prevalent in approximately 9% of men who reported no 
LTPA compared to 5 a nd 4% of men who reported low or high amounts of LTPA.  T he 
prevalence of CKD was also higher in women with approximately 21% of women who reported 
no LTPA having CKD at baseline compared to nearly 12% of women who reported low or high 
levels of LTPA.   
Table 6.9 shows the odds of having CKD by categories of physical activity and gender.  
In women, there was a 1.52 ( 95% confidence interval: 1.05, 2.21)  odds of having CKD at 
baseline in individuals who reported no LTPA compared to individuals who reported high levels 
of LTPA after adjusting for age.   H owever, after adjusting for diabetes status, hypertension, 
HDL cholesterol, and triglyceride levels, this relationship was attenuated and no longer 
significant (OR=1.41; 95% confidence interval: 0.96, 2.08) .  In men, there was also a higher 
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odds of having CKD at baseline in individuals who reported no LTPA compared to individuals 
who reported high levels of LTPA, but the relationship failed to reach significance 
(OR=1.70;95% confidence interval: 0.77, 3.72).   
 
Table 6.9 The cross-sectional relationship between CKD and physical activity by gender 
 Physical 
Activity Levels 
Model 1 Model 2 Model 3 
Men High -- -- -- 
 Low  1.27 (0.66, 2.43) 1.16 (0.60, 2.26) 1.09 (0.55, 2.15) 
 None 1.70 (0.77, 3.72) 1.61 (0.70, 3.66) 1.48 (0.64, 3.41) 
Women     
 High -- -- -- 
 Low  0.98 (0.70, 1.36) 0.99 (0.71, 1.38) 0.89 (0.63, 1.26) 
 None 1.52 (1.05, 2.21) 1.52 (1.04, 2.24) 1.41 (0.96, 2.08) 
Odds ratios (95% Confidence Intervals) 
Model 1: Age adjusted 
Model 2: Model 1 + study site, smoking status, history of heart failure 
Model 3: Model 2 + diabetes status, hypertension, HDL cholesterol, triglycerides 
 
The prevalence of albuminuria was also higher at baseline among individuals who were 
inactive.  A t baseline, albuminuria was prevalent in 35% of men who self-reported no l eisure 
time physical activity (LTPA) compared to approximately 28 and 22% of men who self reported 
low and high levels of physical activity.  The prevalence of albuminuria was higher in women 
who self reported no LTPA (40%) compared to women who self reported low and high levels of 
LTPA (30% and 28% respectively).   
Table 6.10 shows the odds of having albuminuria at baseline by categories of physical 
activity and gender.  Compared to individuals who self reported high levels of LTPA, men and 
women who self reported no LTPA have 1.78 ( 95% confidence interval: 1.29, 2.46)  and 1.94 
(95% confidence interval: 1.52, 2.46) odds of having albuminuria at baseline adjusting for age.  
After adjusting for diabetes status, the relationship between LTPA and albuminuria was no 
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longer significant in men (OR=1.34; 95% confidence interval: 0.93, 1.95).  In women however, 
individuals who self reported no LTPA still had a 1.35 ( 95% confidence interval: 1.04, 1.78)  
odds of having albuminuria compared to women who reported high levels of LTPA. 
 
Table 6.10 The cross-sectional relationship between albuminuria and physical activity by gender 
 Physical 
Activity Levels 
Model 1 Model 2 Model 3 
Men High -- -- -- 
 Low  1.37 (1.06, 1.75) 1.27 (0.98, 1.64) 1.16 (0.87, 1.54) 
 None 1.78 (1.29, 2.46) 1.46 (1.04, 2.05) 1.34 (0.93, 1.95) 
Women     
 High -- -- -- 
 Low  1.32 (1.08, 1.62) 1.20 (0.97, 1.48) 1.03 (0.81, 1.30) 
 None 1.94 (1.52, 2.47) 1.50 (1.16, 1.93) 1.34 (1.01, 1.77) 
Odds ratios (95% Confidence Intervals) 
Model 1: Age adjusted 
Model 2: Model 1 + study site, smoking status 
Model 3: Model 2 + diabetes status, hypertension, HDL cholesterol, triglycerides 
6.1.5 Physical activity and kidney function: Prospective Analysis 
AIM 1a: To determine the relationship between physical activity at baseline 
and change in eGFR during follow-up 
 
HO1a: Individuals who are less physically active at baseline will have a 
greater decrease in renal function compared to individuals who are more active at 
baseline.   
 
At baseline, mean eGFR was similar between men who reported no, l ow, and high levels of 
LTPA (86, 87 and 86 mL/min, p=0.40).  From exam 1 to exam 2, men who reported no LTPA 
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experienced a greater decrease in mean eGFR compared to men who reported low or high 
amounts of LTPA independent of baseline eGFR, albuminuria, age, smoking status, diabetes, 
hypertension, HDL cholesterol, triglycerides, or history of heart failure (p=0.04) (see figure 4).  
The average yearly change in mean eGFR was -1.85, -0.74, and -0.34 mL/min from exam 1 to 
exam 2 in men who reported no, low, and high levels of LTPA respectively.  An rapid decline in 
eGFR was defined as a reduction in eGFR >3 mL/min per year.  A  higher percentage of 
individuals who reported no LTPA experienced rapid declines in eGFR (>3 mL/min) compared 
to individuals who reported low and high levels of LTPA (37, 28, and 23% respectively, 
p<0.01). This increased odds of experiencing accelerated declines in eGFR in the no LTPA 
group was independent of age, smoking status, diabetes, hypertension, HDL cholesterol, 
triglycerides, history of heart failure, baseline eGFR and baseline albuminuria (p=0.01) 
 
Figure 6-2 Mean eGFR by categories of physical activity from exam1 to exam 2 in men 
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In women, mean eGFR at baseline was the same in all three activity groups (78 mL/min).   
The average yearly change in eGFR from exam 1 to exam 2 was -1.76, -1.13, and -0.96 in 
women who reported no, low, and high levels of LTPA respectively.  This change in eGFR was 
not statistically different between the three activity groups (p=0.64) (see figure 5).  H owever, 
when examining individuals who reported no change in their activity status at exam 2, women 
who reported no LTPA have a faster decrease in eGFR compared to women who reported low 
and high levels of LTPA which bordered on s ignificance (p=0.07).  Women who reported no 
LTPA at baseline had higher odds of experiencing rapid declines in kidney controlling for age 
and baseline eGFR (OR=1.37; 95%CI: 1.01, 1.88) .  T his relationship was attenuated and no 
longer significant after further adjusting for diabetes status, hypertension, and baseline 
albuminuria (OR=1.21; 95%CI: 0.88, 1.68).     
 
Figure 6-3 Mean eGFR by categories of physical activity from exam1 to exam 2 in women 
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AIM 1b: To determine the relationship between physical activity at baseline 
and change in albumin to creatinine ratio during follow-up 
 
HO1b: Individuals who are less physically active at baseline will have a 
greater increase in albumin to creatinine ratio compared to individuals who are 
more active at baseline.   
 
At baseline, mean urinary albumin to creatinine ratio(ACR) was higher in men who 
reported no LTPA compared to men who reported low or high amounts of LTPA (men: 98 vs. 61 
and 47 mg/g; p<0.01. Mean ACR increased from exam 1 to exam 2 in all three activity groups 
with men who reported no LTPA had an experiencing a greater increase compared to men who 
reported low or high amounts of LTPA which bordered on significance (p=0.06).  There was a 
further increase in mean ACR from exam 2 to exam 3.  The mean change in ACR from all three 
exam visits were not statistically different from each activity group (p=0.52) (see figure 6).  
When examining individuals who reported no change in their activity levels, individuals who 
reported no LTPA at baseline had a slightly higher increase in ACR from exam 1 to exam 3 





Figure 6-4 Mean urinary albumin to creatinine ratio by categories of physical activity from exam 1 to 
exam 3 in men 
 
In women, mean ACR at baseline was higher in individuals who reported no LTPA 
compared to individuals who reported low and high LTPA (121 vs. 93 and 49 mg/g, p<0.01).  
Mean ACR increased in both exam 2 and exam 3 in all three activity group.     The change in 
mean ACR between the three activity groups was not statistical different (p=0.42) (see figure 7).  
Only examining individuals who reported no change in their activity levels at exam 2 did not 
change the results (p=0.38).    
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Figure 6-5 Mean urinary albumin to creatinine ratio by categories of physical activity from exam 1 to 
exam 3 in women 
 
AIM 2a: To determine the relationship between baseline physical activity 
and the incidence of albuminuria. 
 
HO2a: Individuals who are less physical active at baseline will have a higher 
incidence of albuminuria during follow-up.   
 
Table 6.11 shows the five year incidence (Exam 1 to Exam 2) of albuminuria in men and 
women by categories of physical activity.  Women who reported no LTPA had a 1.82 (95% CI; 
1.23, 2.70) odds of developing albuminuria compared to women who reported high levels of 
LTPA after adjusting for age.  After adjusting for baseline albumin to creatinine ratio, this 
relationship was attenuated and no longer significant (OR=1.39; 95% CI: 0.91, 2.14).  However, 
when examining women who reported an increase in their activity levels at exam 2, individuals 
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who reported no LTPA have baseline had a higher odds of developing albuminuria compared to 
women who reported high levels of LTPA  (OR= 3.0; 95% confidence interval: 1.17, 7.66).    
 In men, individuals who reported no LTPA had a 1.34 odds of developing albuminuria 
adjusting for age, however, the relationship failed to reach significance (95% CI; 0.77, 2.30 ).  
Change in activity levels at exam 2 did not affect the results.   
     
Table 6.11The five year incidence of albuminuria by levels of physical activity and gender 
 Physical 
Activity Levels 
Model 1 Model 2 Model 3 
Men High -- -- -- 
 Low  0.98 (0.65, 1.46) 0.87 (0.56, 1.33) 0.86 (0.47, 1.60) 
 None 1.34 (0.77, 2.30) 0.89 (0.49, 1.63) 0.87 (0.56, 1.35) 
Women     
 High -- -- -- 
 Low  1.28 (0.94, 1.76) 1.16 (0.83, 1.62) 1.12 (0.79, 1.58) 
 None 1.82 (1.23, 2.70) 1.39 (0.91, 2.14) 1.44 (0.93, 2.23) 
Odds ratios (95% Confidence Intervals) 
Model 1: Age adjusted 
Model 2: Model 1 + study site, smoking status, baseline ACR 
Model 3: Model 2 + diabetes status, hypertension, HDL cholesterol, triglycerides 
 
The ten year incidence (Exam 1 to Exam 3) of albuminuria by physical activity categories 
for men and women are shown in Table 6.12.  For men and women, individuals who reported no 
LTPA had a 2.07 ( 95% CI; 1.23, 3.48)  and 1.54 (95% CI; 1.05, 2.26)  odds of developing 
albuminuria compared to individuals who reported high levels of LTPA adjusted for age.  After 
further controlling for current smoking status, study center, and baseline albumin to creatinine 
ratio, this relationship was attenuated and no longer significant.  In men, change in activity levels 
at exam 2 di d not affect the results.  However, in women who reported an increase in their 
activity levels at exam 2, individuals who reported no LTPA at baseline had a 3.52 odds (95% 
 87 
confidence interval; 1.50, 8.23) of developing albuminuria compared to individuals who reported 
high levels of LTPA. 
Table 6.12 The ten year incidence of albuminuria by levels of physical activity and gender 
 Physical 
Activity Level 
Model 1 Model 2 Model 3 
Men High -- -- -- 
 Low  1.12 (0.76, 1.64) 1.06 (0.71, 1.59) 1.16 (0.76, 1.78) 
 None 2.07 (1.23, 3.48) 1.61 (0.92, 2.81) 1.64 (0.91, 2.97) 
Women     
 High -- -- -- 
 Low  1.13 (0.85, 1.49) 1.04 (0.78, 1.40) 1.01 (0.74, 1.38) 
 None 1.54 (1.05, 2.26) 1.23 (0.82, 1.86) 1.40 (0.91, 2.15) 
Odds ratios (95% Confidence Intervals) 
Model 1: Age adjusted 
Model 2: Model 1 + study site, smoking status, baseline ACR 
Model 3: Model 2 + diabetes status, hypertension, HDL cholesterol, triglycerides 
 
AIM 2b: To determine the relationship between baseline physical activity 
and the incidence of CKD. 
 
HO2b: Individuals who are less physical active at baseline will have a higher 
incidence of CKD during follow-up.   
 
Table 6.13 shows the 5 year incidence of CKD by categories of LTPA for men and 
women.  In women, individuals who reported no LTPA had a greater odds of developing CKD 
compared to women who reported high amounts of LTPA after adjusting for age which bordered 
on significance (OR=1.46; 95% CI: 0.99 to 2.15).  When examining individuals who reported a 
decrease in their activity status at exam 2, individuals who reported no LTPA at baseline had a 
higher odds of developing CKD compared to women who reported low or high levels of LTPA 
(OR=2.73; 95% CI: 1.32, 5.65).   
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In men, those who reported no LTPA also had a higher odds of developing CKD 
compared to men who reported high amounts of LTPA, but the relationship failed to reach 
significance after age adjustment (OR=1.34; 95% CI: 0.62 to 2.65).  Change in activity levels at 
exam 2 did not affect the results.     
 
Table 6.13 The five year incidence of CKD by levels of physical activity and gender 
 Physical 
Activity Levels 
Model 1 Model 2 Model 3 
Men High -- -- -- 
 Low  1.33 (0.68, 2.60) 1.25 (0.74, 2.11) 1.25 (0.73, 2.12) 
 None 1.34 (0.81, 2.21) 1.28 (0.62, 2.65) 1.34 (0.64, 2.79) 
Women     
 High -- -- -- 
 Low  1.20 (0.87, 1.64) 1.12 (0.81, 1.57) 1.08 (0.77, 1.50) 
 None 1.46 (0.99, 2.15) 1.31 (0.88, 1.97) 1.28 (0.85, 1.91) 
Odds ratios (95% Confidence Intervals) 
Model 1: Age adjusted 
Model 2: Model 1 + study site, smoking status, history of heart failure, albuminuria 
Model 3: Model 2 + diabetes status, hypertension, HDL cholesterol, triglycerides 
 
6.1.6 Discussion 
This was the first study to examine the relationship between physical activity and renal 
function/CKD in American Indians, a high risk population.  The results of our analysis indicated 
that physical activity at baseline was related to rapid declines in kidney function over a five year 
period, independent of age and baseline eGFR.  These results were similar to published reports 
for the Cardiovascular Health Study (CHS) by Cohen et al [60].  C HS is a community based 
prospective cohort study of men and women of at least 65 years of age.  A rapid decline in renal 
function was defined as having a yearly decrease in eGFR of > 3 m L/min, assessed using 
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cystatin C.  The study indicated that individuals who self reported high levels of physical activity 
had lower odds of having rapid declines in renal function compared to individuals who reported 
low amounts of physical activity.   It’s important to note that CHS was a population of older 
adults who were primarily white and African American which may not be generalizable to 
younger populations. Our results from the SHS show a similar relationship between physical 
activity and renal function in a younger population of American Indians.  These findings provide 
additional evidence that physical activity may aid in slowing the progression of CKD in high risk 
populations.   
In addition to being related to rapid changes in renal function, physical activity was also 
related to albuminuria, which may indicate endothelial dysfunction or kidney damage.  At 
baseline, individuals who reported no LTPA had higher odds of having albuminuria independent 
of age.  Even among individuals without albuminuria at baseline, those who reported no LTPA 
had higher albumin to creatinine ratios in the normal range.  Those individuals with high normal 
levels were more likely to develop albuminuria over the 10 year study follow-up. This may be of 
great importance for American Indian populations considering the high prevalence of 
albuminuria.  Albuminuria was prevalent in approximately 30% of the SHS population compared 
to 13% of the US population based on results from NHANES [256].   
Few studies have looked at the relationship between of physical activity and albuminuria 
prospectively, but the Diabetes Prevention Program (DPP) did compared the prevalence of 
albuminuria in three groups (control, metformin, intense lifestyle: diet, physical activity, and 
weight loss) at baseline and at the study’s end.  While the prevalence of albuminuria (ACR >30 
mg/g)  remained unchanged in the metformin and intense lifestyle intervention groups, a higher 
percentage of individuals in the intensive lifestyle group experienced improvements in 
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albuminuria over the average three and a half years of study follow-up which bordered on 
significance (p=0.07).  Unfortunately, the independent effects of physical activity on albuminuria 
were not examined in the DPP so future studies will have to investigate this relationship more 
thoroughly.   
Physical activity was not however, shown to be related to the development of CKD from 
exam 1 to exam 2.  We w ere able to document that a h igher percentage of individuals who 
reported no LTPA at baseline developed CKD at exam 2.  Approximately 17% of the individuals 
who reported no LTPA at baseline developed CKD compared to 10% of individuals who 
reported high levels of LTPA at baseline.  H owever, we lacked sufficient power to detect a 
difference statistically.  One limitations of this study is that exam 3 used a different assay to 
measure serum creatinine from what was used during the previous 2 e xam cycles.  T his 
prevented us from being able to compare kidney function over all three exam cycles.  It’s 
possible that we may have been able to detect difference in CKD development by physical 
activity with longer follow-up data.     
There were some other important limitations to our analysis.  T he Modifiable Activity 
Questionnaire (MAQ) was used only at baseline to assess physical activity which limits our 
ability to look at the effects of change in activity status on kidney function or CKD development.  
During follow-up exams, individuals were asked if their activity levels had changed from the 
previous exam.  This allowed us to make some crude assessment of change in activity status; 
however, it is not clear if that question is a valid estimate of physical activity stability or change 
over time.  The MAQ also does not provide information on activities of lower intensity.  Given 
the results from paper 2 of this dissertation, light intensity physical activities may contribute to 
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better kidney health.  Future analysis using accelerometry may help elucidate the benefit of light 
intensity activity on CKD.       
Another limitation of this analysis is the lack of control for ACE-inhibitor use at exams 2 
and 3.  ACE-inhibitors are used to treat hypertension and they also have the added benefit of 
reducing urinary albumin excretion.  It is important to establish if the benefits of physical activity 
are independent or in addition to the benefits of pharmacological treatments.  W e were also 
limited by not having the data on mortality, which was collected by the SHS.  Individuals who 
were experiencing rapid declines in the renal function are also more likely to suffer pre-mature 
mortality.  Including mortality for cardiovascular disease or renal complications would likely 
strengthen our study findings.   
Despite the limitations, this study highlights the potential benefits of physical activity for 
kidney function.  This is one of the few studies which examine the relationship between physical 
activity and kidney function prospectively and the only study to do s o in American Indians.  
Given the high risk for CKD in this population, the results of this analysis provide useful 
information for individuals in this population.  Future interventions will have to examine the 
affects of change in physical activity over time and kidney function.   
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7.0  CHAPTER 7 
7.1 CONCLUSIONS 
Chronic kidney disease is a serious public health concern because of the large physical and 
economic burden on society [65].  Because of the large burden of the disease, it is important to 
determine what factors are associated with the development and progression of the disease, 
especially in early stages.  The benefits of physical activity to kidney health have been 
demonstrated in a few studies but there are still many questions which remain unanswered.   
Many studies, which sought to examine the relationship between physical activity and 
chronic disease, used questionnaires to assess physical activity levels.  Questionnaires are 
reasonably accurate for assessing activities of moderate to vigorous intensity. However, it is 
important to note that a large proportion of activity in a typical day occurs in light activity or in 
unplanned movement across various levels of intensity.   Therefore, results of studies that have 
used questionnaires can more accurately investigate the benefits of engaging in moderate to 
vigorous intensity activity for the prevention of various chronic conditions relative to that of light 
intensity or unstructured activity. 
 In paper 1, we described physical activity by intensity in a n ationally representative 
population using accelerometers.   We confirmed the fact that lower intensity activities comprise 
the largest proportion of total movement.  The importance of examining activities of lower 
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intensity is not just that they are being performed in high volume, but that they may make an 
important contribution to our overall health.  This point has yet to be proven in regard to kidney 
function, which is what paper 2 was able to accomplish.   
In paper 2, we were able to follow up on the results from paper 1 and show that lower 
intensity physical activity has important benefits for kidney function.  Using accelerometers, we 
showed that light intensity physical activity was positively associated with kidney function, 
independent of moderate to vigorous intensity activity.  I think it’s worth re-stating that previous 
research, and thus current public health recommendations, has focused on m oderate intensity 
activity as being important for achieving health benefits.  This was a new and exciting finding 
which lends credence to the notion that every step counts.        
Understanding the relationship between various intensities of physical activity and kidney 
function was an important finding, but it is only part of the story.  Cross-sectional relationships 
can only tell us but so much.  We also need  to understand the prospective relationship between 
physical activity and kidney function, which is lacking in the field.  Paper 3 was the first study to 
examine the relationship between physical activity and kidney function/CKD in American 
Indians.  The results of this paper provided evidence that physical activity can potentially 
preserve kidney function even in a population with a high prevalence of kidney damage and 
CKD risk factors.  Not only have we documented the benefit of physical activity on ki dney 
function cross-sectionally, but we now see this relationship prospectively as well.  Unfortunately, 
accelerometers were not used to assess activity during the early stages of the Strong Heart Study 
(SHS), so we were unable to examine the relationship between varying intensities of activity and 
kidney function in paper 3.  If the SHS incorporates accelerometers, in addition to 
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questionnaires, during future examinations, we can explore the relationship between varying 
intensities of activity and kidney function prospectively.  
7.2 PUBLIC HEALTH SIGNIFICANCE 
The results of these three papers provided valuable information on how  varying intensities of 
activity are related to CKD cross-sectionally and for understanding the benefits of moderate 
intensity physical activity prospectively.  With the use of accelerometers we were able to 
document, for the first time, the benefits of lower intensity activity in regard to kidney function.  
More attention should be paid to the idea that total movement counts in addition to our planned 
activities of moderate intensity.  The Canadian physical activity recommendations, for example, 
now include recommendations for accumulating activities of lower intensity in addition to 
moderate intensity activities.  Our findings support these recommendations and there needs to be 
increased awareness about the benefits of physical activity for preserving kidney function.  
According to a survey at the World Congress of Nephrology in 2003, 95% of nephrologists 
surveyed agreed that a sedentary lifestyle contributed to CKD risk.  D espite this, neither the 
Surgeon General’s Report on Physical Activity and Health nor the National Kidney Foundation 
talk about the benefits of physical activity for renal health.  With the growing evidence from this 
effort and the work of others, we may be able to increase awareness. 
In addition to increasing public awareness, this research begins to answer important 
questions about how varying intensities of activities are related to kidney function.  There have 
been previous studies using accelerometers which have focused on m oderate and vigorous 
intensity activity, despite having the ability to incorporate lower intensity activities.  M any 
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researchers have operated under the assumption that the higher intensity activities is where the 
“action” is.  Our public health recommendations over the years have certainly reflected that 
message.  W e now understand that it’s not all about moderate intensity activity but that light 
activity and total volume of movement are also important in relationship to some diseases and 
conditions. This fact needs to be taken into consideration in future studies.  N ow that we 
understand the importance of exploring how varying intensities of activity are related to kidney 
function, we can look to understand the mechanisms of that relationship.   
7.3 FUTURE DIRECTIONS 
The results of this dissertation have produced some new and exciting findings which have 
enhanced our understanding of physical activity and how it relates to kidney function.  However, 
there are some interesting questions which have been raised from these investigations which 
future studies will need to address.  
 In paper 1, we found that Hispanics were more active (light, moderate to vigorous, and 
total activity) than both whites and blacks.  This result was surprising because previous analysis 
of all surveillance system physical activity data, including NHANES, reported Hispanics to be 
less active than whites or blacks.  This raises some important questions about physical activity 
assessment in surveillance systems. The NHANES physical activity questionnaires (PAQ) assess 
activities performed in the household, for transportation, and during leisure time.  One possible 
explanation for the contrasting findings between objective and subjective measures of activity is 
that the PAQ used in NHANES is not a valid assessment tool for Hispanics.  Hispanics may be 
performing activities during leisure which are not capture by the PAQ because the wording of 
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the questions, their activities are spontaneous in nature, or they are performing lower intensity 
activities which the questionnaire are either unable or inaccurate at assessing.  The difficulties in 
assessing activity in diverse populations with a single questionnaire may highlight the 
importance of using objective assessment in those populations.   
Another more likely source of conflict between the two measures may be issues with 
content validity.  The PAQ may perform equally well in all races at assessing activities in the 
household, during transportation, and leisure, it just may fail to include all appropriate domains 
for all the racial/ethnicity groups in the population.   The NHANES PAQ does not include 
occupational activities as part of their assessment.  Potentially, occupational activities may 
comprise a large proportion of activity in Hispanics which is being missed by the PAQ currently 
used in NHANES as well as other surveillance systems.   Future studies should try to figure out 
if content validity is the sources of error which can be corrected by including all appropriate 
domains of activity.   
The results of this dissertation also raise questions about an important debate over the 
value of subjective assessment and what roles questionnaires should play in research.  Some feel 
that objective measures, such as accelerometers, provide the best method for assessing activities 
therefore eliminating the need for questionnaires.  Others feel that subjective assessment has an 
important role when used appropriately.  Now the question is, when is it appropriate to use 
questionnaires?  Some feel the answer to this question is all about intensity.  The thought is that 
when moderate to vigorous activity is most important, than either tool may show the same 
things.   However, when light activity is the critical intensity component, objective assessment 
would likely be the method of choice.   
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In paper 2 we showed that objectively assessed light intensity activity was related to 
kidney function while moderate to vigorous activity (MVPA) assessed objectively or 
subjectively were not.  It would appear that both objective and subjective assessment tools agree 
with each other and gives support to the idea that intensity is an important factor for determining 
when to use subjective or objective assessment.   
With the results of paper 2 s howing that light activity was related to kidney function, 
indicating the need of objective assessment, how do we explain the results from paper 3 which 
showed that subjectively assessed physical activity was related to kidney function?  A re the 
findings from these two papers in conflict with each other?  One the surface it may appear that 
they are.  There are several important factors which must be considered when attempting to 
address these questions.  The first possibility we must consider is that while neither subjectively 
nor objectively assessed moderate to vigorous activity was related to kidney function in paper 2, 
they may have been unrelated for different reasons.   
The lack of a relationship between objectively assessed MVPA via accelerometry and 
kidney function may be due to the lack of variation in activity.  A  large proportion of the 
NHANES population accumulated few minutes of MVPA.  We may have missed a true 
relationship simply because people are not engaging in significant amounts of MVPA as it was 
defined in our study.  We defined MVPA as a minute of activity of 1952 counts using the 
Freedson cutpoint.  Some may argue that that cutpoint is too high for assessing MVPA in the 
general population, especially in older adults.  If this is true, there are some activities that may 
truly be moderate intensity that we classified as light intensity because of the cutpoints we used.  
Using a l ower cutpoint for MVPA may have revealed a significant relationship.  There are 
however concerns with using some of the lower cutpoints which have been proposed by Swartz, 
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Matthews, and others.  The lower cutpoints tend to overestimate resting energy expenditure.  We 
could then classify activities which are light intensity, inaccurately as moderate intensity 
activities.  T his is truly a difficult issue to solve.  F uture studies which use a wide range of 
activities over the complete range of intensity levels may produce more accurate cutpoints. We 
can then have a better idea if MVPA is truly related to kidney function.  
In regards to the questionnaire, the lack of a relationship between subjectively assessed 
physical activity and kidney function in paper may be related to the validity of the NHANES 
PAQ.  Surveillance systems PAQ’s rely on face validity for their development and are often not 
evaluate against a criterion measure.  In paper 3, subjectively assessed physical activity was 
shown to be related to kidney function.  The MAQ however has been developed, pilot tested, and 
validated for use in American Indian populations.  C aspersen and others have shown the 
importance of using a valid measure of physical activity when assessing its relationship with 
cardiovascular disease.  It’s likely that there is a relationship between physical activity and 
kidney function we just need to ensure we are using a valid tool to assess physical activity.   
Another possible explanation for the contrasting findings from papers 2 and 3 is related to 
the characteristics of the NHANES and SHS populations.  The SHS is an older population with a 
higher burden of chronic disease compared to the NHANES population.  Given the high risk of 
disease in the SHS population, individuals who perform activity at any intensity are probably 
less likely to develop CKD than individuals who perform no activity.  The results of the 
questionnaire, which we used to crudely group individuals in no activity and high/low activity, 
was not precise enough to separate out the benefits of the various activity intensities and may just 
be reflecting the fact that individuals who reported high levels of moderate activity probably 
engaged in high amounts of all intensities of activity.  In order to explore this hypothesis further, 
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we could use a validated PAQ and accelerometer in a generally healthy population with a large 
variation of activity levels to see if the results from paper 2 are the same.   
Understanding the situations in which subjectively and objective assessment is most 
appropriate is very important.   It’s likely that intensity of activity does plays an important role 
for determining what assessment tool to use.  This was beyond the scope of our current project 
but it does give us some ideas moving forward.    First, we need to make sure we are using a 
valid and appropriate questionnaire which shows good agreement with a criterion measure.  We 
can then examine the relationship between objectively and subjectively assessed physical activity 
and various health outcomes and determine if questionnaire has good construct validity.     
Lastly, we know that physical activity is related to kidney function.  There are still 
important questions as to how varying intensities of activity is related.  Future studies will need 
to determine if lower intensity activity provides any benefits to preserving kidney function over 
time.   It would also be interesting to know what through what mechanisms varying intensities of 
activity have their affect.  Some have suggested that sedentary behavior is unique associated with 
CKD through lipid metabolism.  M oderate to vigorous intensity activity may affect kidney 
function risk through inflammation, oxidative stress, blood pressure control, or other vascular 
mechanism which have yet to be explored.  Light intensity activities may be related to kidney 
function through similar mechanism as those related to moderate activity, as well as other 
physiological pathways.  There may be statistical procedures, as well as study designs, which can 
help to examine this further.  In the current analysis of the SHS, we used the MAQ to assess 
physical activity.  This allowed us to crudely group individuals into categories of activity.  In 
future analysis of the SHS, we can also incorporate accelerometers to examine the relationship 
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between varying intensities of activities prospectively, but begin to understand their mechanisms 
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